uric acid has been researched along with Albuminuria in 200 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM)." | 9.41 | Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. ( Dronamraju, N; Erlandsson, F; Johansson, S; Johnsson, E; Parkinson, J; Stack, AG; Terkeltaub, R, 2021) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "The NU-FLASH trial demonstrated that febuxostat was more effective for hyperuricemia than allopurinol." | 9.20 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). ( Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H, 2015) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 9.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| "Febuxostat has been reported to have a stronger effect on hyperuricemia than allopurinol." | 9.17 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). ( Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I, 2013) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 9.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "It is still undefined whether serum uric acid (SUA) is an independent risk factor for target organ damage (TOD) and cardiovascular events in human hypertension." | 9.12 | Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. ( Cuspidi, C; Esposito, A; Mancia, G; Meani, S; Sala, C; Valerio, C; Zanchetti, A, 2007) |
| "We examined the renal hemodynamic modifications induced by a selective angiotensin II (AII) AT1 receptor antagonist, losartan, in 10 patients with essential hypertension." | 9.08 | Effects of losartan on renal function in patients with essential hypertension. ( Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996) |
| "To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)." | 8.31 | Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023) |
| " However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification." | 8.12 | Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Leoncini, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2022) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 8.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| "Leveraging a longitudinal cohort including 1981 Chinese adults who had blood pressures, urinary albumin to creatinine ratio (UACR), and uric acid measured twice 4 years apart, we examined the temporal relationships among hyperuricemia, microalbuminuria, and hypertension by cross-lagged panel analysis followed by a causal mediation analysis to confirm the temporal consequence." | 7.96 | Microalbuminuria mediates the association between serum uric acid and elevation of blood pressure: a longitudinal analysis in the Gusu cohort. ( He, Y; Jiang, Y; Li, J; Ma, S; Peng, H; Ren, L; Yu, J; Zhang, M; Zhang, Q, 2020) |
| "To analyze the associations of serum uric acid (SUA) level with diabetic microvascular complications, including diabetic retinopathy (DR) and diabetic nephropathy (DN), in patients with type 2 diabetes mellitus (DM)." | 7.96 | Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. ( Chen, Q; Hou, L; Li, Q; Shi, Y; Wang, S; Zhao, M; Zhou, X, 2020) |
| "Increasing evidence has shown that albuminuria is related to serum uric acid." | 7.88 | Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study. ( Chen, W; Fu, C; Guo, H; Li, F; Lu, Y; Xiao, J; Ye, Z; Zhang, X; Zou, J, 2018) |
| "Metabolic Syndrome (Mets) and increased serum uric acid (SUA), are well known renal risk predictors and often coexist in patients with type 2 diabetes (T2D)." | 7.85 | Metabolic syndrome, serum uric acid and renal risk in patients with T2D. ( Ceriello, A; De Cosmo, S; Fioretto, P; Genovese, S; Giorda, C; Guida, P; Piscitelli, P; Pontremoli, R; Russo, G; Viazzi, F, 2017) |
| "To evaluate the relationship of vitamin D status and vitamin D replacement therapy with glycemic control, serum uric acid (SUA) levels, and microalbuminuria (MAU) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD)." | 7.85 | The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease. ( Acikgoz, SB; Genc, AB; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M, 2017) |
| "To assess the prospective association between baseline serum uric acid level and subsequent risk of development or progression in albuminuria." | 7.83 | Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. ( Hayashino, Y; Ishii, H; Okamura, S; Tsujii, S, 2016) |
| " We evaluated the association between serum uric acid and uACR in persons with 0, and 1-2 metabolic syndrome (MetS) components and determined the modification effects of visceral adiposity index (VAI), mean arterial pressure (MAP), and fasting glucose on this association." | 7.83 | The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. ( Bruthans, J; Cifkova, R; Hamet, P; Krajcoviechova, A; Tahir, MR; Tremblay, J; Wohlfahrt, P, 2016) |
| "Elevated serum uric acid (UA) could be a risk factor for hypertension, type 2 diabetes mellitus and cardiovascular disease." | 7.80 | Serum uric acid level is associated with the development of microalbuminuria in Korean men. ( Oh, CM; Park, SK; Ryoo, JH, 2014) |
| "We assessed the effect of increased serum uric acid (SUA) concentration and hyperuricemia on subclinical organ damage." | 7.80 | Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population. ( Li, Y; Lu, J; Wu, X; Yang, C, 2014) |
| "Elevated albuminuria as well as an increased serum uric acid concentration is associated with poor cardiovascular outcome." | 7.80 | The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. ( Bakker, SJ; de Jong, PE; Gansevoort, RT; Joosten, MM; Scheven, L, 2014) |
| "To assess the relationship between serum uric acid and target organ damage (left ventricular hypertrophy and microalbuminuria) in untreated patients with essential hypertension." | 7.80 | Serum uric acid and target organ damage in essential hypertension. ( Odia, OJ; Ofori, SN, 2014) |
| "To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET-1), microalbuminuria (MAU), intima-media thickness (IMT)) and tubulointerstitial tissue lesion (beta2-microglobulin (beta2-MG, monocyte chemotactic protein-1 (MCP-1))." | 7.80 | [Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder ( Balkarov, IM; Kozlovskaia, LV; Shcherbak, AV; Stakhova, TIu; Taranova, MV, 2014) |
| " The aim of this study was to examine the relationship between serum C-reactive protein (CRP), serum uric acid, and albuminuria in Chinese type 2 diabetic patients." | 7.79 | Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients. ( Gao, X; Li, XM; Ling, Y, 2013) |
| "Acute gout is associated with a decrease in serum uric acid (SUA) that is considered to be in response to acute inflammation but it may be a feature of gout itself." | 7.79 | The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study. ( Ashby, HL; Chugh, S; Deshpande, S; Ford, C; Gama, R; Razavi, C; Thomas, OL; Waldron, JL, 2013) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 7.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| "In the general adult population, elevated serum homocysteine and uric acid were associated with albuminuria independently of each other and of renal function." | 7.77 | Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study. ( Bochud, M; Marques-Vidal, PM; Marti, F; Mooser, V; Paccaud, F; Vollenweider, P; Waeber, G, 2011) |
| "The following factors were selected in the stepwise multivariate model as predictors of micro- or macroalbuminuria at the 6-year follow-up visit: baseline serum uric acid levels, HbA(1c) and pre-albuminuria." | 7.76 | Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. ( Jalal, DI; Johnson, RJ; Maahs, DM; McFann, K; Rewers, M; Rivard, CJ; Snell-Bergeon, JK, 2010) |
| "The aim of the study was to investigate endothelial function in patients with arterial hypertension and impaired uric acid metabolism in comparison with patients having arterial hypertension and normal uric acid metabolism." | 7.76 | [Endothelial function in patients with arterial hypertension and impaired uric acid metabolism]. ( Lebedeva, MV; Minakova, EG; Pulin, AA; Severova, MM; Stakhova, TIu; Zaĭtseva, LI, 2010) |
| "The aim of the study was to assess the association of serum uric acid levels with microalbuminuria -urinary albumin excretion (UAE)> or = 30mg/24h-." | 7.75 | Association between serum uric acid, metabolic syndrome and microalbuminuria in previously untreated essential hypertensive patients. ( Costa, JA; González, C; Miralles, A; Moral, D; Pascual, JM; Pérez-Lahiguera, F; Rodilla, E, 2009) |
| " The aim of this study was to evaluate the relationships between serum uric acid concentration and degree of urinary albumin excretion as well as markers of subclinical atherosclerosis in men with type 2 diabetes mellitus." | 7.74 | Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. ( Asano, M; Fukui, M; Harusato, I; Hasegawa, G; Hosoda, H; Kadono, M; Nakamura, N; Shiraishi, E; Tanaka, M; Yoshikawa, T, 2008) |
| " Lipid profiles, ACR, bilirubin, uric acid, creatine kinase, and hsCRP were not changed in DM patients with different diabetic duration or diabetic retinopathy." | 7.73 | Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. ( Chang, MH; Chen, TH; Chen, YJ; Hsu, HH; Huang, CY; Huang, EJ; Kuo, WW; Lee, SD; Lu, MC; Tzang, BS, 2006) |
| "To analyse relationships between left ventricular myocardium mass (LVMM) and imbalance of uric acid metabolism in patients with arterial hypertension (AH)." | 7.71 | [Relationship between mass of the left ventricular myocardium and uric acid metabolic imbalance in patients with arterial hypertension]. ( Anikina, SA; Balkarov, IM; Donskov, AS; Feofanova, ID; Golub', GV; Prilepo, NA; Saltykova, NG; Sviderskaia, NS, 2001) |
| "The N-acetyl-beta-D-glucosaminidase (NAG) activities and albumin levels in the urine of 32 patients with active rheumatoid arthritis treated with low-dose pulse methotrexate (MTX) have been investigated." | 7.69 | N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. ( Swierkot, J; Szechiński, J; Wiland, P, 1997) |
| "In order to help clarify the effects of hyperthyroidism on renal function and electrolyte metabolism, we measured the venous plasma concentrations of urea, creatinine, urate, hydrogen ion and electrolytes, and the urinary concentrations of total protein, albumin, retinol-binding protein, N-acetyl-beta-D-glucosaminidase activity, and creatinine in patients when hyperthyroid and again after they had been euthyroid for at least 4 months." | 7.67 | Renal function and electrolyte levels in hyperthyroidism: urinary protein excretion and the plasma concentrations of urea, creatinine, uric acid, hydrogen ion and electrolytes. ( Chisnall, WN; Ford, HC; Lim, WC; Pearce, JM, 1989) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Patients with type 2 diabetes mellitus (DM) may experience chronic microvascular complications such as diabetic retinopathy (DR) and diabetic nephropathy (DN) during their lifetime." | 5.43 | Association of Serum Uric Acid Concentration with Diabetic Retinopathy and Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus. ( Chen, SC; Hsiao, PJ; Hsu, WH; Lee, MY; Liang, CC; Lin, KD; Lin, PC; Shin, SJ, 2016) |
| " We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM)." | 5.41 | Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. ( Dronamraju, N; Erlandsson, F; Johansson, S; Johnsson, E; Parkinson, J; Stack, AG; Terkeltaub, R, 2021) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 5.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH (+), n=305 and LVH (-), n=537]." | 5.33 | The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. ( Antoniadis, D; Chatzis, D; Dimitriadis, K; Kallikazaros, I; Lalos, S; Stefanadis, C; Toutouzas, P; Tsioufis, C; Vezali, E; Zervoudaki, A, 2005) |
| " The secondary outcome was the change in albuminuria and serum uric acid (UA)." | 5.22 | The Effect of Allopurinol on Renal Outcomes in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. ( Chen, L; Duan, Q; He, D; Wu, B; Xu, Y; Zheng, Z, 2022) |
| "The NU-FLASH trial demonstrated that febuxostat was more effective for hyperuricemia than allopurinol." | 5.20 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). ( Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H, 2015) |
| "Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database." | 5.20 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. ( de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B, 2015) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 5.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| "Febuxostat has been reported to have a stronger effect on hyperuricemia than allopurinol." | 5.17 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). ( Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I, 2013) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 5.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "Patients with arterial hypertension of the first-second degree with persistent elevated levels of uric acid in blood serum had significantly higher levels of ED markers: albuminuria, plasmic endothelin concentration." | 5.15 | [Clinical implication of endothelial dysfunction in patients with essential arterial hypertension and urate dysbolism with renal damage]. ( , 2011) |
| "It is still undefined whether serum uric acid (SUA) is an independent risk factor for target organ damage (TOD) and cardiovascular events in human hypertension." | 5.12 | Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. ( Cuspidi, C; Esposito, A; Mancia, G; Meani, S; Sala, C; Valerio, C; Zanchetti, A, 2007) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "We examined the renal hemodynamic modifications induced by a selective angiotensin II (AII) AT1 receptor antagonist, losartan, in 10 patients with essential hypertension." | 5.08 | Effects of losartan on renal function in patients with essential hypertension. ( Berra, N; Fauvel, JP; Laville, M; Madonna, O; Pozet, N; Velon, S; Zech, P, 1996) |
| "The acute and chronic effects of pinacidil on blood pressure (BP) and renal function were investigated in 10 patients with moderate arterial hypertension insufficiently controlled by chronic beta-blockade." | 5.06 | Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy. ( Christensen, CK; Krusell, LR; Lederballe Pedersen, O, 1986) |
| "The acute effects of buccal nifedipine 20 mg on blood pressure, renal haemodynamics and electrolyte excretion were compared in 16 untreated patients (HT) with uncomplicated arterial hypertension (WHO I-II), 11 normotensives (NT) and 6 normotensives given a placebo." | 5.06 | Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls--a proximal tubular effect? ( Christensen, CK; Krusell, LR; Lederballe Pedersen, O, 1987) |
| " SGLT2 inhibitors can decrease blood pressure levels and serum uric acid levels and may also reduce the degree of diabetes-related albuminuria." | 4.95 | Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. ( Elisaf, MS; Filippatos, TD; Tsimihodimos, V, 2017) |
| " Early markers of CVD such as microalbuminuria and uric acid levels need to be added to the routine annual evaluation, particularly among high-risk individuals such as diabetics, hypertensives, smokers, and the elderly." | 4.85 | Chronic kidney disease: a marker of cardiovascular disease. ( Nguyen, PT; Olivero, JJ, 2009) |
| "To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)." | 4.31 | Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023) |
| "Previous studies suggested that increased serum uric acid (SUA) level is an independent risk factor for albuminuria in Type 2 diabetes (T2D) patients." | 4.12 | Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations. ( An, X; Sun, J; Tian, R; Wang, X; Yu, J; Zhou, Y; Zhu, L, 2022) |
| " However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification." | 4.12 | Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Leoncini, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2022) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 4.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| " We observed an improvement of renal function biomarkers (estimated-glomerular filtration rate, albuminuria, azotemia, uric acid), lipid profile, oxidative stress, inflammatory parameters (erythrocyte sedimentation rate, C-reactive protein) and in body composition at T1." | 4.02 | Usefulness of Extra Virgin Olive Oil Minor Polar Compounds in the Management of Chronic Kidney Disease Patients. ( Di Daniele, F; Di Daniele, N; Di Lauro, M; Marrone, G; Noce, A; Pietroboni Zaitseva, A; Romani, A; Urciuoli, S, 2021) |
| "Leveraging a longitudinal cohort including 1981 Chinese adults who had blood pressures, urinary albumin to creatinine ratio (UACR), and uric acid measured twice 4 years apart, we examined the temporal relationships among hyperuricemia, microalbuminuria, and hypertension by cross-lagged panel analysis followed by a causal mediation analysis to confirm the temporal consequence." | 3.96 | Microalbuminuria mediates the association between serum uric acid and elevation of blood pressure: a longitudinal analysis in the Gusu cohort. ( He, Y; Jiang, Y; Li, J; Ma, S; Peng, H; Ren, L; Yu, J; Zhang, M; Zhang, Q, 2020) |
| " The mechanism of development of hyperuricemia (defined, serum uric acid (UA) ≥ 5." | 3.96 | Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients. ( Beach, I; Feig, D; Kaspar, CDW; Newlin, J; Sisler, I; Smith, W, 2020) |
| "To analyze the associations of serum uric acid (SUA) level with diabetic microvascular complications, including diabetic retinopathy (DR) and diabetic nephropathy (DN), in patients with type 2 diabetes mellitus (DM)." | 3.96 | Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. ( Chen, Q; Hou, L; Li, Q; Shi, Y; Wang, S; Zhao, M; Zhou, X, 2020) |
| "In this study, we aimed to analyze the relationship between serum uric acid (UA) and microalbuminuria as a marker of renal injury in type 2 diabetes mellitus." | 3.91 | Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy? ( Aktas, G; Atak, BM; Duman, TT; Kocak, MZ; Savli, H, 2019) |
| " This review discussed the non-glycemic effects of SGLT-2is in patients with T2D and renal impairment, including reductions in systolic and diastolic blood pressure, decreases in albuminuria and plasma uric acid, changes in estimated glomerular filtration rate, and minimal changes in electrolytes." | 3.91 | Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. ( Weir, MR, 2019) |
| "Hyperuricemia is a risk factor for causing end-stage kidney disease and cardiovascular disease in the general population; however, several aspects, such as the site of kidney damaged by hyperuricemia and the threshold levels of serum uric acid for the development of renal damage, have not been fully clarified." | 3.88 | The Association between Serum Uric Acid and Renal Damage: The Takahata Study - New Insights. ( Ichikawa, K; Kamei, K; Kayama, T; Konta, T; Kubota, I, 2018) |
| "Increasing evidence has shown that albuminuria is related to serum uric acid." | 3.88 | Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study. ( Chen, W; Fu, C; Guo, H; Li, F; Lu, Y; Xiao, J; Ye, Z; Zhang, X; Zou, J, 2018) |
| "Metabolic Syndrome (Mets) and increased serum uric acid (SUA), are well known renal risk predictors and often coexist in patients with type 2 diabetes (T2D)." | 3.85 | Metabolic syndrome, serum uric acid and renal risk in patients with T2D. ( Ceriello, A; De Cosmo, S; Fioretto, P; Genovese, S; Giorda, C; Guida, P; Piscitelli, P; Pontremoli, R; Russo, G; Viazzi, F, 2017) |
| " Multivariable analysis using eGFRcreat as an independent variable identified age, smoking status, body mass index, haemoglobin, serum uric acid, serum albumin, albuminuria, and C reactive protein as non-GFR determinants of eGFRcys." | 3.85 | The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. ( Fluck, RJ; Fraser, SDS; McIntyre, CW; McIntyre, NJ; Raftery, J; Roderick, P; Shardlow, A; Taal, MW, 2017) |
| "To evaluate the relationship of vitamin D status and vitamin D replacement therapy with glycemic control, serum uric acid (SUA) levels, and microalbuminuria (MAU) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD)." | 3.85 | The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease. ( Acikgoz, SB; Genc, AB; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M, 2017) |
| "To assess the prospective association between baseline serum uric acid level and subsequent risk of development or progression in albuminuria." | 3.83 | Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. ( Hayashino, Y; Ishii, H; Okamura, S; Tsujii, S, 2016) |
| " Renal function parameters, namely, creatinine, estimated glomerular filtration rate (eGFR), urea, uric acid, urine specific gravity, microalbuminuria, and proteinuria were collected and their values were compared the day before the race (T1), immediately after crossing the finish line (T2), and 18 to 24 hours after the competition (T3)." | 3.83 | Can Solid-Organ-Transplanted Patients Perform a Cycling Marathon? Trends in Kidney Function Parameters in Comparison With Healthy Subjects. ( Angelini, ML; Balzi, W; Cappuccilli, M; Costa, AN; Mosconi, G; Roi, GS; Storani, D; Tonioli, M; Totti, V; Trerotola, M, 2016) |
| " Multiple linear regression analysis using eGFR as the dependent variable demonstrated that uric acid (UA), FFA, triglyceride (TG), total cholesterol (TC), albuminuria, hypertension, smoking and duration of diabetes were all independent risk factors for decreased eGFR (all P<0." | 3.83 | [Correlation between serum free fatty acid level and estimated glomerular filtration rate in type 2 diabetic patients]. ( Li, H; Lin, X; Xuan, L; Yin, X; Zheng, F; Zhu, W, 2016) |
| " We evaluated the association between serum uric acid and uACR in persons with 0, and 1-2 metabolic syndrome (MetS) components and determined the modification effects of visceral adiposity index (VAI), mean arterial pressure (MAP), and fasting glucose on this association." | 3.83 | The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. ( Bruthans, J; Cifkova, R; Hamet, P; Krajcoviechova, A; Tahir, MR; Tremblay, J; Wohlfahrt, P, 2016) |
| " Measurements included clinical and ambulatory blood pressure monitoring, ultrasound-measured flow-mediated dilatation (FMD), microalbuminuria, carotid intima-media thickness (CIMT) and serum uric acid, as well as clinical and demographic features." | 3.81 | Persistence of cardiovascular risk factors in women with previous preeclampsia: a long-term follow-up study. ( Acmaz, G; Afsar, B; Aykas, F; Bulut, K; Covic, A; Dogan, S; Erden, A; Johnson, RJ; Kanbay, M; Sarli, B; Sharma, S; Siriopol, D; Solak, Y, 2015) |
| "We recruited 43 chronic kidney disease (CKD) patients who did not receive RAS blockers and antihyperuricaemic drugs, and investigated the relationship among serum uric acid (sUA) levels, the circadian rhythm of urinary angiotensinogen (U-AGT) excretion levels, and the levels of albuminuria (U-ACR) and proteinuria (U-P/Cr)." | 3.81 | Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms. ( Ishigaki, S; Isobe, S; Iwakura, T; Kato, A; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2015) |
| " There were positive correlations between NAFLD and insulin resistance index (HOMA-IR), free fatty acids (FFA), tumor necrosis factor-α (TNF-α), omentin-1, visceral fat area, homocysteine (HCY), and serum uric acid (UA)." | 3.81 | Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. ( Di, F; Gao, L; Jia, G; Li, N; Li, Q; Shao, J; Wang, L; Wang, Q, 2015) |
| "Elevated serum uric acid (UA) could be a risk factor for hypertension, type 2 diabetes mellitus and cardiovascular disease." | 3.80 | Serum uric acid level is associated with the development of microalbuminuria in Korean men. ( Oh, CM; Park, SK; Ryoo, JH, 2014) |
| "We assessed the effect of increased serum uric acid (SUA) concentration and hyperuricemia on subclinical organ damage." | 3.80 | Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population. ( Li, Y; Lu, J; Wu, X; Yang, C, 2014) |
| "Elevated albuminuria as well as an increased serum uric acid concentration is associated with poor cardiovascular outcome." | 3.80 | The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. ( Bakker, SJ; de Jong, PE; Gansevoort, RT; Joosten, MM; Scheven, L, 2014) |
| "To assess the relationship between serum uric acid and target organ damage (left ventricular hypertrophy and microalbuminuria) in untreated patients with essential hypertension." | 3.80 | Serum uric acid and target organ damage in essential hypertension. ( Odia, OJ; Ofori, SN, 2014) |
| " The relationship between albuminuria and circulating biomarkers for both oxidative damage, that is carbonyl and malondialdehyde, as well as antioxidant defense, that is reduced glutathione, thiol groups, uric acid, bilirubin, or catalase, and superoxide scavenging activity, was assessed." | 3.80 | Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. ( Aranguez, I; Arribas, S; Cerezo, C; Condezo-Hoyos, L; Del Carmen Gónzalez, M; Fernández-Alfonso, MS; Praga, M; Pulido-Olmo, H; Ruilope, LM; Ruiz-Hurtado, G; Segura, J, 2014) |
| "To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET-1), microalbuminuria (MAU), intima-media thickness (IMT)) and tubulointerstitial tissue lesion (beta2-microglobulin (beta2-MG, monocyte chemotactic protein-1 (MCP-1))." | 3.80 | [Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder ( Balkarov, IM; Kozlovskaia, LV; Shcherbak, AV; Stakhova, TIu; Taranova, MV, 2014) |
| " Lower measured GFR associated with lower 24-hour urine creatinine, albuminuria, hypertension, diabetes, higher triglycerides, and higher uric acid." | 3.79 | Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. ( Bailey, KR; Lieske, JC; Peyser, PA; Rule, AD; Turner, ST, 2013) |
| " The aim of this study was to examine the relationship between serum C-reactive protein (CRP), serum uric acid, and albuminuria in Chinese type 2 diabetic patients." | 3.79 | Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients. ( Gao, X; Li, XM; Ling, Y, 2013) |
| "Acute gout is associated with a decrease in serum uric acid (SUA) that is considered to be in response to acute inflammation but it may be a feature of gout itself." | 3.79 | The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study. ( Ashby, HL; Chugh, S; Deshpande, S; Ford, C; Gama, R; Razavi, C; Thomas, OL; Waldron, JL, 2013) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 3.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| " But quercetin was only partially effective in restoring glomerular filtration rate, albuminuria, serum cholesterol, triglyceride, blood urea nitrogen (BUN), uric acid, malondialdehyde, superoxide dismutase; urinary BUN and urinary creatinine." | 3.78 | Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease. ( Chen, KC; Hsieh, CL; Ker, YB; Peng, CC; Peng, RY; Wang, HY, 2012) |
| "In the general adult population, elevated serum homocysteine and uric acid were associated with albuminuria independently of each other and of renal function." | 3.77 | Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study. ( Bochud, M; Marques-Vidal, PM; Marti, F; Mooser, V; Paccaud, F; Vollenweider, P; Waeber, G, 2011) |
| "The prevalence of albuminuria increases gradually with uric acid elevation." | 3.77 | [The relationship between urinary albumin excretion and serum uric acid in general population]. ( Cai, JF; Fan, XH; Gao, BX; Li, H; Li, JH; Li, XM; Li, XW; Liu, LL; Liu, XJ; Meng, QY; Mou, LJ; Wang, HY; Wu, JX, 2011) |
| "The following factors were selected in the stepwise multivariate model as predictors of micro- or macroalbuminuria at the 6-year follow-up visit: baseline serum uric acid levels, HbA(1c) and pre-albuminuria." | 3.76 | Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. ( Jalal, DI; Johnson, RJ; Maahs, DM; McFann, K; Rewers, M; Rivard, CJ; Snell-Bergeon, JK, 2010) |
| " The cut-off point varied in subjects with various cardiovascular risk profiles such as serum uric acid level, gender or hypertension." | 3.76 | Very low-grade albuminuria reflects susceptibility to chronic kidney disease in combination with cardiovascular risk factors. ( Ahn, JM; Chae, DW; Chin, HJ; Heo, NJ; Kim, S; Lee, TW; Na, KY, 2010) |
| "The aim of the study was to investigate endothelial function in patients with arterial hypertension and impaired uric acid metabolism in comparison with patients having arterial hypertension and normal uric acid metabolism." | 3.76 | [Endothelial function in patients with arterial hypertension and impaired uric acid metabolism]. ( Lebedeva, MV; Minakova, EG; Pulin, AA; Severova, MM; Stakhova, TIu; Zaĭtseva, LI, 2010) |
| "The aim of the study was to assess the association of serum uric acid levels with microalbuminuria -urinary albumin excretion (UAE)> or = 30mg/24h-." | 3.75 | Association between serum uric acid, metabolic syndrome and microalbuminuria in previously untreated essential hypertensive patients. ( Costa, JA; González, C; Miralles, A; Moral, D; Pascual, JM; Pérez-Lahiguera, F; Rodilla, E, 2009) |
| " The aim of this study was to evaluate the relationships between serum uric acid concentration and degree of urinary albumin excretion as well as markers of subclinical atherosclerosis in men with type 2 diabetes mellitus." | 3.74 | Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. ( Asano, M; Fukui, M; Harusato, I; Hasegawa, G; Hosoda, H; Kadono, M; Nakamura, N; Shiraishi, E; Tanaka, M; Yoshikawa, T, 2008) |
| "The respective uric acid levels for normoalbuminuria (N= 166), microalbuminuria (N= 130), and macroalbuminuria (N= 47) were 5." | 3.73 | Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. ( Tseng, CH, 2005) |
| " Lipid profiles, ACR, bilirubin, uric acid, creatine kinase, and hsCRP were not changed in DM patients with different diabetic duration or diabetic retinopathy." | 3.73 | Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. ( Chang, MH; Chen, TH; Chen, YJ; Hsu, HH; Huang, CY; Huang, EJ; Kuo, WW; Lee, SD; Lu, MC; Tzang, BS, 2006) |
| " After adjustment for the degree of obesity, subjects with MS had significantly higher uric acid (6." | 3.73 | Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors. ( Gilardini, L; Girola, A; Invitti, C; Maffeis, C; Mazzilli, G; Morabito, F; Pontiggia, B; Sartorio, A; Viberti, GC, 2006) |
| " The aim of our study was to evaluate the relation of SPECT result to diabetes compensation, presence of micro/macroalbuminuria, blood level of fibrinogen, CRP, homocysteine and uric acid." | 3.72 | [Relation between diabetes compensation, albuminuria and biochemical parameters and the results of stress myocardial SPECT in asymptomatic type 2 diabetics]. ( Charvát, J; Chlumský, J; Kvapil, M; Michalová, K; Táborská, K; Vojácek, J, 2004) |
| "To analyse relationships between left ventricular myocardium mass (LVMM) and imbalance of uric acid metabolism in patients with arterial hypertension (AH)." | 3.71 | [Relationship between mass of the left ventricular myocardium and uric acid metabolic imbalance in patients with arterial hypertension]. ( Anikina, SA; Balkarov, IM; Donskov, AS; Feofanova, ID; Golub', GV; Prilepo, NA; Saltykova, NG; Sviderskaia, NS, 2001) |
| " Patients within the lowest C-peptide quartile showed significantly higher duration of diabetes, prevalence of retinopathy and values of HDL-cholesterol, albumin excretion rate and HbA1c, while BMI, diastolic blood pressure, percentages of hypertension and metabolic syndrome, and values of triglycerides and uric acid were significantly higher in the highest C-peptide quartile." | 3.70 | Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. ( Bo, S; Cavallo-Perin, P; Gentile, L; Pagano, G; Repetti, E, 2000) |
| "The N-acetyl-beta-D-glucosaminidase (NAG) activities and albumin levels in the urine of 32 patients with active rheumatoid arthritis treated with low-dose pulse methotrexate (MTX) have been investigated." | 3.69 | N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. ( Swierkot, J; Szechiński, J; Wiland, P, 1997) |
| "In order to help clarify the effects of hyperthyroidism on renal function and electrolyte metabolism, we measured the venous plasma concentrations of urea, creatinine, urate, hydrogen ion and electrolytes, and the urinary concentrations of total protein, albumin, retinol-binding protein, N-acetyl-beta-D-glucosaminidase activity, and creatinine in patients when hyperthyroid and again after they had been euthyroid for at least 4 months." | 3.67 | Renal function and electrolyte levels in hyperthyroidism: urinary protein excretion and the plasma concentrations of urea, creatinine, uric acid, hydrogen ion and electrolytes. ( Chisnall, WN; Ford, HC; Lim, WC; Pearce, JM, 1989) |
| "The effects on blood pressure and renal function of a single 20-mg sublingual dose of nifedipine were investigated in 10 patients with mild to moderate arterial hypertension insufficiently treated on beta-blocker monotherapy." | 3.66 | Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta-adrenoceptor-blocking drugs. ( Christensen, CK; Lederballe Pedersen, O; Mikkelsen, E, 1982) |
| "Hyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression." | 2.80 | Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. ( Asahi, K; Hayashi, Y; Kanno, M; Kimura, H; Nakayama, M; Tanaka, K; Tani, Y; Terawaki, H; Watanabe, K; Watanabe, T, 2015) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Hypertension is an established risk factor of cardiovascular morbidity and mortality." | 2.52 | [The First Step Aiming at the Prevention of Hypertension and Atherosclerosis. Identification of Individuals at High Risk of Hypertension]. ( Dohi, Y, 2015) |
| "Renal functional changes in diabetic nephropathy conventionally have been linked to progression of urinary albumin excretion." | 2.44 | Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy. ( Ficociello, LH; Krolewski, AS; Niewczas, MA; Perkins, BA; Rosolowsky, ET; Warram, JH, 2008) |
| "Uric acid is a waste metabolite produced from the breakdown of purines, and elevated serum uric acid levels are associated with higher risk of hypertension, cardiovascular disease, and mortality and progression of chronic kidney disease (CKD)." | 1.72 | Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease. ( Hassan, W; Kalantar-Zadeh, K; Kovesdy, CP; Potukuchi, PK; Rhee, CM; Shrestha, P; Streja, E; Sumida, K; Sweeney, PL; Thomas, F, 2022) |
| "In older men, albuminuria is an independent predictor of subsequent cognitive decline." | 1.62 | Markers of Kidney Function and Longitudinal Cognitive Ability Among Older Community-Dwelling Adults: The Rancho Bernardo Study. ( Alcaraz, JE; LaCroix, AZ; Laughlin, GA; McEvoy, LK; Oren, E; Richard, EL; Salem, RM, 2021) |
| "We recruited 98 Taiwanese patients with type 2 diabetes and 10 patients with early chronic kidney disease (CKD) into this study." | 1.51 | Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy. ( Chen, CM; Chen, HL; Kuo, CW; Tu, MY, 2019) |
| "Although hyperuricemia is shown to accelerate chronic kidney disease, the mechanisms remain unclear." | 1.46 | Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats. ( Asakawa, S; Hosoyamada, M; Kumagai, T; Morimoto, C; Nakamura, T; Shibata, S; Shiraishi, T; Tamura, Y; Uchida, S, 2017) |
| "Prehypertension is a risk factor for the development of hypertension and other cardiovascular diseases." | 1.46 | Subclinical target organ damage in normotensive and prehypertensive patients. ( Chen, YH; Yi, H; Zhang, H; Zhang, WZ; Zhou, MC, 2017) |
| "A total of 127 IgA nephropathy patients with microalbuminuria were followed up successfully, with an average follow-up of (49." | 1.43 | [Clinico-pathological characteristics and prognosis of IgA nephropathy patients with microalbuminuria and deposition of complement C3]. ( Du, XY; Guo, ZY; Li, X; Wang, YY; Wu, YM; Xu, Y; Zhang, W; Zhou, SG, 2016) |
| "Patients with type 2 diabetes mellitus (DM) may experience chronic microvascular complications such as diabetic retinopathy (DR) and diabetic nephropathy (DN) during their lifetime." | 1.43 | Association of Serum Uric Acid Concentration with Diabetic Retinopathy and Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus. ( Chen, SC; Hsiao, PJ; Hsu, WH; Lee, MY; Liang, CC; Lin, KD; Lin, PC; Shin, SJ, 2016) |
| "Uric acid may cause renal damage, whereas adiponectin in some studies has been reported to have renoprotective properties." | 1.43 | The Association Between Adiponectin, Serum Uric Acid and Urinary Markers of Renal Damage in the General Population: Cross-Sectional Data from the Tromsø Study. ( Eggen, AE; Eriksen, BO; Jenssen, TG; Kronborg, JB; Melsom, T; Norvik, JV; Solbu, MD; Storhaug, HM; Zykova, SN, 2016) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 1.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "Diabetic nephropathy is the kidney disease that occurs as a result of diabetes." | 1.40 | Protective effect of bioflavonoid myricetin enhances carbohydrate metabolic enzymes and insulin signaling molecules in streptozotocin-cadmium induced diabetic nephrotoxic rats. ( Ashokkumar, N; Kandasamy, N, 2014) |
| "Hypertension was not independently associated with measures of nephron hypertrophy." | 1.40 | Nephron hypertrophy and glomerulosclerosis and their association with kidney function and risk factors among living kidney donors. ( Alexander, MP; Elsherbiny, HE; Kremers, WK; Lieske, JC; Park, WD; Poggio, ED; Prieto, M; Rule, AD, 2014) |
| "147 patients (61 women and 86 men) with type 1 diabetes without increased urine albumin excretion were analysed." | 1.40 | Serum uric acid concentration is associated with early changes of glomerular filtration rate in patients with diabetes type 1 without increased albumin excretion. ( Korzeniewska-Dyl, I; Moczulski, D; Spaleniak, S, 2014) |
| "Eighteen rats with diabetic nephropathy and 6 rats without induced nephropathy were divided into 4 groups, each containing 6 animals." | 1.39 | Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats. ( Jose, MA; Kumar, BN; Sathyamurthy, D; Sheela, N, 2013) |
| "Hyperuricemia is now regarded as a risk factor for cardiovascular disease." | 1.39 | Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in taiwan. ( Chang, HY; Hsu, YC; Huang, TJ; Lee, PH; Lei, CC; Lin, CL; Lu, LC; Tung, CW, 2013) |
| "Hyperuricemia is a risk factor for end-stage renal disease." | 1.39 | The association between serum uric acid and renal damage in a community-based population: the Takahata study. ( Ichikawa, K; Ikeda, A; Kato, T; Kayama, T; Konta, T; Kubota, I; Kudo, K; Sato, H; Suzuki, K; Ueno, Y, 2013) |
| "By analysing factors associated with diabetic nephropathy rather than microvascular disease in general, this study provides evidence that night-time diastolic BP and a relative increase in platelet count are associated with incipient diabetic nephropathy." | 1.38 | Factors associated with diabetic nephropathy in subjects with proliferative retinopathy. ( Buhagiar, G; Calleja, N; Fava, S; Magri, CJ; Vassallo, J, 2012) |
| "Twenty-eight women with mild preeclampsia and 22 with severe preeclampsia at Nanfang Hospital, Southern Medical University between October 2010 and June 2011 were recruited." | 1.38 | [Diagnostic value of radom spot albuminuria to creatinine ratio in women with preeclampsia]. ( Gao, YF; Huang, QT; Leng, LZ; Wang, W; Wang, Y; Wang, ZJ; Yu, YH; Zhong, M, 2012) |
| "Mulberroside A is a major stilbene glycoside of MORUS ALBA L." | 1.37 | Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice. ( Hu, LS; Kong, LD; Wang, CP; Wang, X; Wang, Y; Ye, JF; Zhang, X, 2011) |
| "INTRODUCTION." | 1.37 | Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. ( Bonakdaran, S; Hami, M; Shakeri, MT, 2011) |
| "The metabolic syndrome was defined based on the criteria of the Chinese Diabetes Society (CDS)." | 1.36 | The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. ( Chen, B; Chen, Y; Ni, Z; Xu, W; Yang, D; Ye, B, 2010) |
| "We found a clear dose-response relation between serum uric acid and risk of early GFR loss in patients with type 1 diabetes." | 1.36 | High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. ( Aschengrau, A; Doria, A; Eckfeldt, JH; Ficociello, LH; Galecki, AT; Krolewski, AS; Maselli, NJ; Niewczas, MA; Rosolowsky, ET; Stanton, RC; Warram, JH; Weinberg, JM, 2010) |
| "Uric acid was measured 3 years after onset of diabetes and before any patient developed microalbuminuria." | 1.35 | Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. ( Hovind, P; Johnson, RJ; Parving, HH; Rossing, P; Tarnow, L, 2009) |
| "Allopurinol treatment significantly lowered uric acid levels, reduced albuminuria, and ameliorated tubulointerstitial injury, but it did not prevent mesangial expansion." | 1.35 | Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. ( Heinig, M; Johnson, RJ; Kosugi, T; Nakagawa, T; Nakayama, T; Roncal, C; Sanchez-Lozada, LG; Yuzawa, Y; Zhang, L, 2009) |
| "Patients with type 1 diabetes and normoalbuminuria or microalbuminuria were recruited to the Second Joslin Kidney Study." | 1.35 | High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. ( Binns, AL; Ficociello, LH; Krolewski, AS; Maselli, NJ; Niewczas, MA; Roshan, B; Rosolowsky, ET; Warram, JH, 2008) |
| "Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH (+), n=305 and LVH (-), n=537]." | 1.33 | The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. ( Antoniadis, D; Chatzis, D; Dimitriadis, K; Kallikazaros, I; Lalos, S; Stefanadis, C; Toutouzas, P; Tsioufis, C; Vezali, E; Zervoudaki, A, 2005) |
| "Metabolic syndrome is associated with subclinical organ damage in nondiabetic, essential hypertensive patients." | 1.33 | Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. ( Deferrari, G; Falqui, V; Leoncini, G; Parodi, A; Parodi, D; Pontremoli, R; Ratto, E; Tomolillo, C; Vaccaro, V; Viazzi, F, 2005) |
| "Pre-eclampsia and eclampsia are associated with higher levels of cord blood erythropoietin." | 1.31 | Estimation of cord blood erythropoietin in pre-eclampsia and eclampsia. ( Dhawan, V; Ganguly, NK; Gupta, G; Gupta, I; Suri, V, 2000) |
| "While obesity was not associated with microalbuminuria once central adiposity was taken into account, elevated percent body fat remained associated with microalbuminuria." | 1.31 | Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. ( Döring, A; Hense, HW; Keil, U; Liese, AD; Stieber, J, 2001) |
| "The incidence of preeclampsia was significantly associated with increasing urinary albumin excretion rate, primiparity, and ambulatory blood pressure." | 1.31 | Ambulatory blood pressure as predictor of preeclampsia in diabetic pregnancies with respect to urinary albumin excretion rate and glycemic regulation. ( Klebe, JG; Klebe, TM; Lauszus, FF; Lousen, T; Rasmussen, OW, 2001) |
| "We conclude that PIDDM patients have more severe renal dysfunction than NIDDM patients and, since glycosylated haemoglobin concentrations are comparable in these groups, we attribute this to a renal insult due to malnutrition predating the onset of the PIDDM." | 1.30 | Kidney function in phasic insulin dependent diabetes mellitus in Jamaica. ( Bennett, F; Morrison, EY; Ragoobirsingh, D, 1997) |
| "To investigate the possible effect of preeclampsia on erythropoietin metabolism, we measured plasma and urine erythropoietin concentrations and complete blood count in 19 women with preeclampsia and nine healthy gravidas." | 1.28 | Erythropoietin in preeclampsia. ( Gonzales, E; Kaupke, CJ; Powers, DR; Vaziri, ND, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (9.50) | 18.7374 |
| 1990's | 22 (11.00) | 18.2507 |
| 2000's | 38 (19.00) | 29.6817 |
| 2010's | 95 (47.50) | 24.3611 |
| 2020's | 26 (13.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, C | 1 |
| Wang, Y | 3 |
| Li, J | 3 |
| Gao, J | 1 |
| Luan, Z | 1 |
| Cui, X | 1 |
| Ren, H | 1 |
| Cherney, DZI | 1 |
| Bjornstad, P | 1 |
| Perkins, BA | 2 |
| Rosenstock, J | 1 |
| Neubacher, D | 1 |
| Marquard, J | 1 |
| Soleymanlou, N | 1 |
| Lai, YJ | 1 |
| Chen, YY | 1 |
| Ku, PW | 1 |
| Chen, LJ | 1 |
| Yen, YF | 1 |
| Hassan Al-Bayati, AA | 1 |
| Jawad Al-Khateeb, SM | 1 |
| Wu, B | 1 |
| Chen, L | 1 |
| Xu, Y | 3 |
| Duan, Q | 1 |
| Zheng, Z | 2 |
| He, D | 1 |
| Hassan, W | 1 |
| Shrestha, P | 1 |
| Sumida, K | 1 |
| Thomas, F | 1 |
| Sweeney, PL | 1 |
| Potukuchi, PK | 1 |
| Rhee, CM | 1 |
| Streja, E | 1 |
| Kalantar-Zadeh, K | 1 |
| Kovesdy, CP | 1 |
| Ma, Y | 1 |
| Wang, Q | 2 |
| Chen, Y | 3 |
| Su, J | 1 |
| Gao, Q | 1 |
| Fan, Y | 1 |
| Feng, J | 1 |
| Liu, M | 1 |
| He, Q | 1 |
| Lin, Y | 1 |
| Ma, B | 1 |
| Yang, Y | 1 |
| Huang, J | 1 |
| Li, W | 1 |
| Yu, X | 1 |
| Liang, L | 1 |
| Zhu, L | 1 |
| Sun, J | 1 |
| Wang, X | 2 |
| Tian, R | 1 |
| Zhou, Y | 2 |
| Yu, J | 2 |
| An, X | 1 |
| Choi, Y | 1 |
| Jacobs, DR | 1 |
| Kramer, HJ | 1 |
| Shroff, GR | 1 |
| Chang, AR | 1 |
| Duprez, DA | 1 |
| Mukherjee, D | 1 |
| Mikhailidis, DP | 2 |
| Yang, N | 1 |
| Chou, H | 1 |
| Shi, L | 1 |
| Wei, M | 1 |
| Li, Y | 3 |
| Kocak, MZ | 1 |
| Aktas, G | 1 |
| Duman, TT | 1 |
| Atak, BM | 1 |
| Savli, H | 1 |
| Wołyniec, W | 1 |
| Kasprowicz, K | 1 |
| Giebułtowicz, J | 1 |
| Korytowska, N | 1 |
| Zorena, K | 1 |
| Bartoszewicz, M | 1 |
| Rita-Tkachenko, P | 1 |
| Renke, M | 1 |
| Ratkowski, W | 1 |
| Jiang, Y | 1 |
| Zhang, Q | 2 |
| Ren, L | 1 |
| He, Y | 1 |
| Ma, S | 1 |
| Zhang, M | 1 |
| Peng, H | 2 |
| Kaspar, CDW | 1 |
| Beach, I | 1 |
| Newlin, J | 1 |
| Sisler, I | 1 |
| Feig, D | 1 |
| Smith, W | 1 |
| Kanbay, M | 2 |
| Girerd, N | 1 |
| Machu, JL | 1 |
| Bozec, E | 1 |
| Duarte, K | 1 |
| Boivin, JM | 1 |
| Wagner, S | 1 |
| Ferreira, JP | 1 |
| Zannad, F | 1 |
| Rossignol, P | 1 |
| Sun, X | 1 |
| Liu, J | 1 |
| Wang, G | 1 |
| Cai, A | 1 |
| Liu, L | 1 |
| Siddiqui, M | 1 |
| Zhou, D | 1 |
| Chen, J | 1 |
| Calhoun, DA | 1 |
| Tang, S | 1 |
| Feng, Y | 1 |
| Al Za'abi, M | 1 |
| Al Salam, S | 1 |
| Al Suleimani, Y | 1 |
| Ashique, M | 1 |
| Manoj, P | 1 |
| Nemmar, A | 1 |
| Ali, BH | 1 |
| Itano, S | 1 |
| Kadoya, H | 1 |
| Satoh, M | 1 |
| Nakamura, T | 2 |
| Murase, T | 1 |
| Sasaki, T | 1 |
| Kanwar, YS | 1 |
| Kashihara, N | 1 |
| Stack, AG | 1 |
| Dronamraju, N | 1 |
| Parkinson, J | 1 |
| Johansson, S | 1 |
| Johnsson, E | 1 |
| Erlandsson, F | 1 |
| Terkeltaub, R | 1 |
| Hou, L | 1 |
| Shi, Y | 1 |
| Wang, S | 1 |
| Chen, Q | 1 |
| Li, Q | 2 |
| Zhao, M | 1 |
| Zhou, X | 2 |
| Jalal, DI | 2 |
| Chertow, GM | 1 |
| Noce, A | 1 |
| Marrone, G | 1 |
| Urciuoli, S | 1 |
| Di Daniele, F | 1 |
| Di Lauro, M | 1 |
| Pietroboni Zaitseva, A | 1 |
| Di Daniele, N | 1 |
| Romani, A | 1 |
| Russo, E | 1 |
| Viazzi, F | 7 |
| Pontremoli, R | 7 |
| Barbagallo, CM | 1 |
| Bombelli, M | 1 |
| Casiglia, E | 1 |
| Cicero, AFG | 1 |
| Cirillo, M | 1 |
| Cirillo, P | 1 |
| Desideri, G | 1 |
| D'Elia, L | 1 |
| Ferri, C | 1 |
| Galletti, F | 1 |
| Gesualdo, L | 1 |
| Giannattasio, C | 1 |
| Iaccarino, G | 1 |
| Leoncini, G | 5 |
| Mallamaci, F | 1 |
| Maloberti, A | 1 |
| Masi, S | 1 |
| Mengozzi, A | 1 |
| Mazza, A | 1 |
| Muiesan, ML | 2 |
| Nazzaro, P | 1 |
| Palatini, P | 1 |
| Parati, G | 2 |
| Rattazzi, M | 1 |
| Rivasi, G | 1 |
| Salvetti, M | 1 |
| Tikhonoff, V | 1 |
| Tocci, G | 1 |
| Ungar, A | 1 |
| Verdecchia, P | 1 |
| Virdis, A | 1 |
| Volpe, M | 2 |
| Grassi, G | 1 |
| Borghi, C | 1 |
| Richard, EL | 1 |
| McEvoy, LK | 1 |
| Oren, E | 1 |
| Alcaraz, JE | 1 |
| Laughlin, GA | 1 |
| LaCroix, AZ | 1 |
| Salem, RM | 1 |
| Asakawa, S | 1 |
| Shibata, S | 1 |
| Morimoto, C | 1 |
| Shiraishi, T | 1 |
| Tamura, Y | 1 |
| Kumagai, T | 1 |
| Hosoyamada, M | 1 |
| Uchida, S | 3 |
| Piscitelli, P | 1 |
| Giorda, C | 2 |
| Ceriello, A | 2 |
| Genovese, S | 1 |
| Russo, G | 1 |
| Guida, P | 1 |
| Fioretto, P | 2 |
| De Cosmo, S | 2 |
| Shardlow, A | 1 |
| McIntyre, NJ | 2 |
| Fraser, SDS | 1 |
| Roderick, P | 1 |
| Raftery, J | 1 |
| Fluck, RJ | 2 |
| McIntyre, CW | 2 |
| Taal, MW | 2 |
| Klisic, A | 1 |
| Kocic, G | 1 |
| Kavaric, N | 1 |
| Jovanovic, M | 1 |
| Stanisic, V | 1 |
| Ninic, A | 1 |
| Pilemann-Lyberg, S | 2 |
| Persson, F | 1 |
| Frystyk, J | 1 |
| Rossing, P | 4 |
| Konta, T | 2 |
| Kamei, K | 1 |
| Ichikawa, K | 2 |
| Kayama, T | 2 |
| Kubota, I | 2 |
| Chai, T | 1 |
| Zhang, D | 1 |
| Li, Z | 1 |
| Fu, S | 1 |
| Guo, Y | 1 |
| Zhang, Z | 1 |
| Luo, L | 1 |
| Ye, P | 1 |
| Li, F | 1 |
| Guo, H | 1 |
| Zou, J | 1 |
| Chen, W | 1 |
| Lu, Y | 1 |
| Zhang, X | 2 |
| Fu, C | 1 |
| Xiao, J | 1 |
| Ye, Z | 1 |
| Kuo, CW | 1 |
| Chen, HL | 1 |
| Tu, MY | 1 |
| Chen, CM | 1 |
| Mazidi, M | 1 |
| Katsiki, N | 1 |
| Banach, M | 1 |
| Russo, GT | 1 |
| Krajcoviechova, A | 3 |
| Marois-Blanchet, FC | 1 |
| Troyanov, S | 1 |
| Harvey, F | 1 |
| Dumas, P | 1 |
| Tremblay, J | 3 |
| Cifkova, R | 3 |
| Awadalla, P | 1 |
| Madore, F | 1 |
| Hamet, P | 3 |
| Hansen, TW | 1 |
| Tofte, N | 1 |
| Winther, SA | 1 |
| Theilade, S | 1 |
| Ahluwalia, TS | 1 |
| Chen, MY | 1 |
| Wang, AP | 1 |
| Wang, JW | 1 |
| Ke, JF | 1 |
| Yu, TP | 1 |
| Li, LX | 1 |
| Jia, WP | 1 |
| Weir, MR | 2 |
| Fayed, A | 1 |
| El Nokeety, MM | 1 |
| Heikal, AA | 1 |
| Sadek, KM | 1 |
| Hammad, H | 1 |
| Abdulazim, DO | 1 |
| Salem, MM | 1 |
| Sharaf El Din, UA | 1 |
| Rule, AD | 2 |
| Bailey, KR | 1 |
| Lieske, JC | 2 |
| Peyser, PA | 1 |
| Turner, ST | 1 |
| Sheela, N | 1 |
| Jose, MA | 1 |
| Sathyamurthy, D | 1 |
| Kumar, BN | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Chang, HY | 1 |
| Lee, PH | 1 |
| Lei, CC | 1 |
| Tung, CW | 1 |
| Hsu, YC | 1 |
| Huang, TJ | 1 |
| Lu, LC | 1 |
| Lin, CL | 1 |
| Diallo, D | 1 |
| Dubourg, L | 1 |
| Ranchin, B | 1 |
| Cochat, P | 1 |
| Bacchetta, J | 1 |
| Sezai, A | 2 |
| Soma, M | 3 |
| Nakata, K | 2 |
| Hata, M | 1 |
| Yoshitake, I | 1 |
| Wakui, S | 1 |
| Hata, H | 2 |
| Shiono, M | 2 |
| Krolewski, AS | 4 |
| Niewczas, MA | 4 |
| Skupien, J | 1 |
| Gohda, T | 1 |
| Smiles, A | 1 |
| Eckfeldt, JH | 2 |
| Doria, A | 2 |
| Warram, JH | 4 |
| Oh, CM | 1 |
| Park, SK | 1 |
| Ryoo, JH | 1 |
| Ling, Y | 1 |
| Li, XM | 2 |
| Gao, X | 1 |
| Lu, J | 1 |
| Wu, X | 1 |
| Yang, C | 1 |
| Hosoya, T | 1 |
| Ohno, I | 1 |
| Nomura, S | 1 |
| Hisatome, I | 1 |
| Fujimori, S | 1 |
| Yamamoto, T | 1 |
| Hara, S | 1 |
| Wiwanitkit, V | 1 |
| Garneri, D | 1 |
| Gonnella, A | 1 |
| Ambrosioni, E | 1 |
| Costa, FV | 1 |
| Leonetti, G | 1 |
| Pessina, AC | 1 |
| Trimarco, B | 1 |
| Agabiti Rosei, E | 1 |
| Deferrari, G | 4 |
| Mulè, G | 1 |
| Riccobene, R | 1 |
| Castiglia, A | 1 |
| D'Ignoto, F | 1 |
| Ajello, E | 1 |
| Geraci, G | 1 |
| Guarino, L | 1 |
| Nardi, E | 1 |
| Vaccaro, F | 1 |
| Cerasola, G | 1 |
| Cottone, S | 1 |
| Ran, J | 1 |
| Ma, J | 1 |
| Liu, Y | 1 |
| Tan, R | 1 |
| Liu, H | 1 |
| Lao, G | 1 |
| Scheven, L | 2 |
| Joosten, MM | 1 |
| de Jong, PE | 3 |
| Bakker, SJ | 2 |
| Gansevoort, RT | 3 |
| Ofori, SN | 1 |
| Odia, OJ | 1 |
| Kandasamy, N | 1 |
| Ashokkumar, N | 1 |
| Ruiz-Hurtado, G | 1 |
| Condezo-Hoyos, L | 1 |
| Pulido-Olmo, H | 1 |
| Aranguez, I | 1 |
| Del Carmen Gónzalez, M | 1 |
| Arribas, S | 1 |
| Cerezo, C | 1 |
| Segura, J | 1 |
| Praga, M | 1 |
| Fernández-Alfonso, MS | 1 |
| Ruilope, LM | 1 |
| Stakhova, TIu | 2 |
| Shcherbak, AV | 1 |
| Kozlovskaia, LV | 1 |
| Taranova, MV | 1 |
| Balkarov, IM | 4 |
| Takahashi, M | 1 |
| Sugawara, M | 1 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Fujita, M | 1 |
| Mochizuki, K | 1 |
| Shin, I | 1 |
| Morita, T | 1 |
| Hikita, T | 1 |
| Itakura, H | 1 |
| Takahashi, Y | 1 |
| Mizuno, S | 1 |
| Ohno, Y | 1 |
| Ito, K | 1 |
| Ito, T | 1 |
| Robinson-Cohen, C | 1 |
| Hall, YN | 1 |
| Katz, R | 1 |
| Rivara, MB | 1 |
| de Boer, IH | 1 |
| Kestenbaum, BR | 1 |
| Himmelfarb, J | 1 |
| Elsherbiny, HE | 1 |
| Alexander, MP | 1 |
| Kremers, WK | 1 |
| Park, WD | 1 |
| Poggio, ED | 1 |
| Prieto, M | 1 |
| Spaleniak, S | 1 |
| Korzeniewska-Dyl, I | 1 |
| Moczulski, D | 1 |
| Osaka, S | 1 |
| Ishii, Y | 1 |
| Yaoita, H | 1 |
| Tanaka, K | 1 |
| Nakayama, M | 1 |
| Kanno, M | 1 |
| Kimura, H | 1 |
| Watanabe, K | 1 |
| Tani, Y | 1 |
| Hayashi, Y | 1 |
| Asahi, K | 1 |
| Terawaki, H | 1 |
| Watanabe, T | 1 |
| Aykas, F | 1 |
| Solak, Y | 2 |
| Erden, A | 1 |
| Bulut, K | 1 |
| Dogan, S | 1 |
| Sarli, B | 1 |
| Acmaz, G | 1 |
| Afsar, B | 1 |
| Siriopol, D | 1 |
| Covic, A | 1 |
| Sharma, S | 1 |
| Johnson, RJ | 4 |
| Kasiske, BL | 1 |
| Anderson-Haag, T | 1 |
| Israni, AK | 1 |
| Kalil, RS | 1 |
| Kimmel, PL | 1 |
| Kraus, ES | 1 |
| Kumar, R | 1 |
| Posselt, AA | 1 |
| Pesavento, TE | 1 |
| Rabb, H | 1 |
| Steffes, MW | 1 |
| Snyder, JJ | 1 |
| Schievink, B | 1 |
| de Zeeuw, D | 2 |
| Parving, HH | 2 |
| Lambers Heerspink, HJ | 1 |
| Ohashi, N | 1 |
| Ishigaki, S | 1 |
| Isobe, S | 1 |
| Tsuji, N | 1 |
| Iwakura, T | 1 |
| Ono, M | 1 |
| Tsuji, T | 1 |
| Sakao, Y | 1 |
| Kato, A | 1 |
| Yasuda, H | 1 |
| Patricio, JA | 1 |
| Lopes, PF | 1 |
| Medeiros, T | 1 |
| Mendes, GF | 1 |
| Silva, AA | 1 |
| Esberard, EB | 1 |
| Lugon, JR | 1 |
| Almeida, JR | 1 |
| Jia, G | 1 |
| Di, F | 1 |
| Shao, J | 1 |
| Gao, L | 1 |
| Wang, L | 1 |
| Li, N | 1 |
| Storhaug, HM | 2 |
| Toft, I | 1 |
| Norvik, JV | 2 |
| Jenssen, T | 1 |
| Eriksen, BO | 2 |
| Melsom, T | 2 |
| Løchen, ML | 1 |
| Solbu, MD | 2 |
| Yi, H | 1 |
| Zhang, WZ | 1 |
| Zhang, H | 1 |
| Chen, YH | 1 |
| Zhou, MC | 1 |
| Hayashino, Y | 1 |
| Okamura, S | 1 |
| Tsujii, S | 1 |
| Ishii, H | 1 |
| Dohi, Y | 1 |
| Guo, ZY | 1 |
| Zhou, SG | 1 |
| Wang, YY | 1 |
| Li, X | 1 |
| Du, XY | 1 |
| Zhang, W | 1 |
| Wu, YM | 1 |
| Guo, Q | 1 |
| Luo, W | 1 |
| Yin, DS | 1 |
| Jia, CY | 1 |
| Mosconi, G | 1 |
| Angelini, ML | 1 |
| Balzi, W | 1 |
| Totti, V | 1 |
| Roi, GS | 1 |
| Cappuccilli, M | 1 |
| Tonioli, M | 1 |
| Storani, D | 1 |
| Trerotola, M | 1 |
| Costa, AN | 1 |
| Xuan, L | 1 |
| Zheng, F | 1 |
| Lin, X | 1 |
| Zhu, W | 1 |
| Yin, X | 1 |
| Li, H | 2 |
| Takae, K | 1 |
| Nagata, M | 1 |
| Hata, J | 1 |
| Mukai, N | 1 |
| Hirakawa, Y | 1 |
| Yoshida, D | 1 |
| Kishimoto, H | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Kiyohara, Y | 1 |
| Ninomiya, T | 1 |
| Cheng, D | 1 |
| Zhao, J | 1 |
| Jian, L | 1 |
| Ding, T | 1 |
| Liu, S | 1 |
| Liang, CC | 1 |
| Lin, PC | 1 |
| Lee, MY | 1 |
| Chen, SC | 1 |
| Shin, SJ | 1 |
| Hsiao, PJ | 1 |
| Lin, KD | 1 |
| Hsu, WH | 1 |
| Wohlfahrt, P | 2 |
| Bruthans, J | 2 |
| Tahir, MR | 2 |
| Eggen, AE | 1 |
| Zykova, SN | 1 |
| Kronborg, JB | 1 |
| Jenssen, TG | 1 |
| Tsimihodimos, V | 1 |
| Filippatos, TD | 1 |
| Elisaf, MS | 1 |
| Sipahi, S | 1 |
| Acikgoz, SB | 1 |
| Genc, AB | 1 |
| Yildirim, M | 1 |
| Tamer, A | 1 |
| Tsuda, K | 1 |
| Ahola, AJ | 1 |
| Sandholm, N | 1 |
| Forsblom, C | 1 |
| Harjutsalo, V | 1 |
| Dahlström, E | 1 |
| Groop, PH | 1 |
| Ma, C | 1 |
| Sheng, J | 1 |
| Liu, Z | 1 |
| Guo, M | 1 |
| Rosolowsky, ET | 3 |
| Ficociello, LH | 3 |
| Rodilla, E | 1 |
| Pérez-Lahiguera, F | 1 |
| Costa, JA | 1 |
| González, C | 1 |
| Miralles, A | 1 |
| Moral, D | 1 |
| Pascual, JM | 1 |
| Hovind, P | 1 |
| Tarnow, L | 1 |
| Kosugi, T | 1 |
| Nakayama, T | 1 |
| Heinig, M | 1 |
| Zhang, L | 1 |
| Yuzawa, Y | 1 |
| Sanchez-Lozada, LG | 1 |
| Roncal, C | 1 |
| Nakagawa, T | 1 |
| Chen, CC | 1 |
| Wu, JY | 1 |
| Chang, CT | 1 |
| Tsai, FJ | 1 |
| Wang, TY | 1 |
| Liu, YM | 1 |
| Tsui, HC | 1 |
| Chen, RH | 1 |
| Chiou, SC | 1 |
| Frank, H | 1 |
| Graf, J | 2 |
| Amann-Gassner, U | 1 |
| Bratke, R | 1 |
| Daniel, H | 1 |
| Heemann, U | 1 |
| Hauner, H | 1 |
| Rivard, CJ | 1 |
| Maahs, DM | 1 |
| McFann, K | 1 |
| Rewers, M | 1 |
| Snell-Bergeon, JK | 1 |
| Olivero, JJ | 2 |
| Nguyen, PT | 1 |
| Chen, B | 1 |
| Yang, D | 1 |
| Xu, W | 1 |
| Ye, B | 1 |
| Ni, Z | 1 |
| Maselli, NJ | 2 |
| Weinberg, JM | 1 |
| Aschengrau, A | 1 |
| Stanton, RC | 1 |
| Galecki, AT | 1 |
| Heo, NJ | 1 |
| Ahn, JM | 1 |
| Lee, TW | 1 |
| Chin, HJ | 1 |
| Na, KY | 1 |
| Chae, DW | 1 |
| Kim, S | 1 |
| Endo, M | 1 |
| Kumakura, H | 1 |
| Kanai, H | 1 |
| Araki, Y | 1 |
| Kasama, S | 1 |
| Sumino, H | 1 |
| Ichikawa, S | 1 |
| Kurabayashi, M | 1 |
| Wang, CP | 1 |
| Ye, JF | 1 |
| Hu, LS | 1 |
| Kong, LD | 1 |
| Bonakdaran, S | 1 |
| Hami, M | 1 |
| Shakeri, MT | 1 |
| Akl, K | 1 |
| Lebedeva, MV | 3 |
| Minakova, EG | 1 |
| Zaĭtseva, LI | 1 |
| Severova, MM | 1 |
| Pulin, AA | 1 |
| Magri, CJ | 1 |
| Calleja, N | 1 |
| Buhagiar, G | 1 |
| Fava, S | 1 |
| Vassallo, J | 1 |
| Silver, SA | 1 |
| Huang, M | 1 |
| Nash, MM | 1 |
| Prasad, GV | 1 |
| Marti, F | 1 |
| Vollenweider, P | 1 |
| Marques-Vidal, PM | 1 |
| Mooser, V | 1 |
| Waeber, G | 1 |
| Paccaud, F | 1 |
| Bochud, M | 1 |
| Fan, XH | 1 |
| Cai, JF | 1 |
| Gao, BX | 1 |
| Mou, LJ | 1 |
| Li, JH | 1 |
| Liu, XJ | 1 |
| Wu, JX | 1 |
| Meng, QY | 1 |
| Wang, HY | 2 |
| Liu, LL | 1 |
| Li, XW | 1 |
| Resl, M | 1 |
| Clodi, M | 1 |
| Neuhold, S | 1 |
| Kromoser, H | 1 |
| Riedl, M | 1 |
| Vila, G | 1 |
| Prager, R | 1 |
| Pacher, R | 1 |
| Strunk, G | 1 |
| Luger, A | 1 |
| Hülsmann, M | 1 |
| Ding, J | 1 |
| Peng, Y | 1 |
| Chao, X | 1 |
| Tian, H | 1 |
| Zhang, Y | 1 |
| Cai, XL | 1 |
| Han, XY | 1 |
| Ji, LN | 1 |
| Ueda, T | 1 |
| Kai, H | 1 |
| Imaizumi, T | 1 |
| Forman, JP | 1 |
| Curhan, GC | 1 |
| Gao, YF | 1 |
| Huang, QT | 1 |
| Zhong, M | 1 |
| Wang, W | 1 |
| Wang, ZJ | 1 |
| Leng, LZ | 1 |
| Yu, YH | 1 |
| Lee, IT | 1 |
| Hung, YJ | 1 |
| Chen, JF | 1 |
| Wang, CY | 1 |
| Lee, WJ | 1 |
| Sheu, WH | 1 |
| Peng, CC | 1 |
| Hsieh, CL | 1 |
| Ker, YB | 1 |
| Chen, KC | 1 |
| Peng, RY | 1 |
| Suzuki, K | 1 |
| Kudo, K | 1 |
| Sato, H | 1 |
| Ikeda, A | 1 |
| Ueno, Y | 1 |
| Kato, T | 1 |
| Waldron, JL | 1 |
| Ashby, HL | 1 |
| Razavi, C | 1 |
| Thomas, OL | 1 |
| Chugh, S | 1 |
| Deshpande, S | 1 |
| Ford, C | 1 |
| Gama, R | 1 |
| Tylicki, L | 1 |
| Manitius, J | 1 |
| Łysiak-Szydłowska, W | 1 |
| Rutkowski, B | 1 |
| Qublan, HS | 1 |
| Al-Kaisi, IJ | 1 |
| Hindawi, IM | 1 |
| Hiasat, MS | 1 |
| Awamleh, I | 1 |
| Hamaideh, AH | 1 |
| Abd-Alghani, I | 1 |
| Sou'ub, RM | 1 |
| Abu-Jassar, H | 1 |
| Al-Maitah, M | 1 |
| GROSS, A | 1 |
| DELATTE, P | 1 |
| VINIAKER, H | 1 |
| SADOUL, P | 1 |
| Kade, G | 1 |
| Wierzbicki, P | 1 |
| Prokopiuk-Wierzbicka, M | 1 |
| Wańkowicz, Z | 1 |
| Tsioufis, C | 1 |
| Chatzis, D | 1 |
| Vezali, E | 1 |
| Dimitriadis, K | 1 |
| Antoniadis, D | 1 |
| Zervoudaki, A | 1 |
| Lalos, S | 1 |
| Kallikazaros, I | 1 |
| Stefanadis, C | 1 |
| Toutouzas, P | 1 |
| Charvát, J | 1 |
| Michalová, K | 1 |
| Táborská, K | 1 |
| Chlumský, J | 1 |
| Kvapil, M | 1 |
| Vojácek, J | 1 |
| Parodi, D | 2 |
| Parodi, A | 3 |
| Falqui, V | 3 |
| Ratto, E | 3 |
| Vettoretti, S | 1 |
| Bezante, GP | 1 |
| Del Sette, M | 1 |
| Vaccaro, V | 2 |
| Tomolillo, C | 2 |
| Tseng, CH | 1 |
| Huang, EJ | 1 |
| Kuo, WW | 1 |
| Chen, YJ | 1 |
| Chen, TH | 1 |
| Chang, MH | 1 |
| Lu, MC | 1 |
| Tzang, BS | 1 |
| Hsu, HH | 1 |
| Huang, CY | 1 |
| Lee, SD | 1 |
| Lee, JE | 1 |
| Kim, YG | 1 |
| Choi, YH | 1 |
| Huh, W | 1 |
| Kim, DJ | 1 |
| Oh, HY | 1 |
| Invitti, C | 2 |
| Maffeis, C | 1 |
| Gilardini, L | 2 |
| Pontiggia, B | 2 |
| Mazzilli, G | 2 |
| Girola, A | 1 |
| Sartorio, A | 2 |
| Morabito, F | 1 |
| Viberti, GC | 1 |
| Matavelli, LC | 1 |
| Frohlich, ED | 1 |
| Cuspidi, C | 1 |
| Valerio, C | 1 |
| Sala, C | 1 |
| Meani, S | 1 |
| Esposito, A | 1 |
| Zanchetti, A | 1 |
| Mancia, G | 1 |
| Conti, N | 1 |
| Wakabayashi, I | 1 |
| Masuda, H | 1 |
| Abe, H | 1 |
| Minatoguchi, S | 1 |
| Ohashi, H | 1 |
| Murata, I | 1 |
| Minagawa, T | 1 |
| Okuma, T | 1 |
| Yokoyama, H | 1 |
| Takatsu, H | 1 |
| Takaya, T | 1 |
| Nagano, T | 1 |
| Osumi, Y | 1 |
| Kakami, M | 1 |
| Tsukamoto, T | 1 |
| Tanaka, T | 1 |
| Hiei, K | 1 |
| Fujiwara, H | 1 |
| Torun, D | 1 |
| Ozelsancak, R | 1 |
| Turan, I | 1 |
| Micozkadioglu, H | 1 |
| Sezer, S | 1 |
| Ozdemir, FN | 1 |
| Binns, AL | 1 |
| Roshan, B | 1 |
| Fukui, M | 1 |
| Tanaka, M | 1 |
| Shiraishi, E | 1 |
| Harusato, I | 1 |
| Hosoda, H | 1 |
| Asano, M | 1 |
| Kadono, M | 1 |
| Hasegawa, G | 1 |
| Yoshikawa, T | 1 |
| Nakamura, N | 1 |
| Pinelli, M | 1 |
| Bindi, M | 1 |
| Moroni, F | 1 |
| Castiglioni, M | 1 |
| Heyden-Stucki, S | 1 |
| Schibler-Reich, S | 1 |
| Andreasen, F | 1 |
| Hansen, U | 1 |
| Husted, SE | 1 |
| Mogensen, CE | 1 |
| Christensen, CK | 3 |
| Lederballe Pedersen, O | 3 |
| Mikkelsen, E | 1 |
| Shahinfar, S | 1 |
| Redfield, A | 1 |
| Eggenberger, M | 1 |
| Bruno, G | 1 |
| Cavallo-Perin, P | 2 |
| Bargero, G | 1 |
| Borra, M | 1 |
| Calvi, V | 1 |
| D'Errico, N | 1 |
| Deambrogio, P | 1 |
| Pagano, G | 2 |
| Lukicheva, TI | 2 |
| Aleksandrovskaia, TN | 1 |
| Oleĭnikova, EB | 1 |
| Kozlova, VG | 1 |
| Shovskaia, TN | 1 |
| Crepaldi, G | 1 |
| Manzato, E | 1 |
| Fauvel, JP | 1 |
| Velon, S | 1 |
| Berra, N | 1 |
| Pozet, N | 1 |
| Madonna, O | 1 |
| Zech, P | 1 |
| Laville, M | 1 |
| Wiland, P | 1 |
| Swierkot, J | 1 |
| Szechiński, J | 1 |
| Ragoobirsingh, D | 1 |
| Bennett, F | 1 |
| Morrison, EY | 1 |
| Mattei, P | 1 |
| Arzilli, F | 1 |
| Giovannetti, R | 1 |
| Penno, G | 1 |
| Arrighi, P | 1 |
| Taddei, S | 1 |
| Salvetti, A | 1 |
| Olofsson, P | 1 |
| Poulsen, H | 1 |
| Guidi, E | 1 |
| Giglioni, A | 1 |
| Cozzi, MG | 1 |
| Minetti, EE | 1 |
| Men'shikov, VV | 1 |
| Mukhin, NA | 1 |
| Varshavskĭ, VA | 1 |
| Proskurneva, EP | 1 |
| Aleksandrovaskaia, TN | 1 |
| Shionoiri, H | 1 |
| Sugimoto, K | 1 |
| Kosaka, T | 1 |
| Kita, E | 1 |
| Oda, H | 1 |
| Ushikubo, T | 1 |
| Goto, T | 1 |
| Takasaki, I | 1 |
| Yasuda, G | 1 |
| Pérez-Blanco, FJ | 1 |
| Sanabria, MC | 1 |
| Huertas, JM | 1 |
| Cantero, J | 1 |
| Rodríguez-Cuartero, A | 1 |
| Gentile, S | 1 |
| Turco, S | 1 |
| Torella, R | 1 |
| Nishijo, M | 1 |
| Nakagawa, H | 1 |
| Morikawa, Y | 1 |
| Miura, K | 1 |
| Tabata, M | 1 |
| Ishizaki, M | 1 |
| Tomura, S | 1 |
| Kawada, K | 1 |
| Saito, K | 1 |
| Lin, YL | 1 |
| Endou, K | 1 |
| Hirano, C | 1 |
| Yanagi, H | 1 |
| Tsuchiya, S | 1 |
| Shiba, K | 1 |
| Martínez, MA | 2 |
| García-Puig, J | 1 |
| Martín, JC | 1 |
| Guallar-Castillón, P | 1 |
| Aguirre de Cárcer, A | 1 |
| Torre, A | 2 |
| Armada, E | 1 |
| Nevado, A | 2 |
| Madero, RS | 1 |
| Bichler, K | 1 |
| Mittermüller, B | 1 |
| Strohmaier, WL | 1 |
| Feil, G | 1 |
| Eipper, E | 1 |
| Poortmans, JR | 1 |
| Dellalieux, O | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Gupta, G | 1 |
| Gupta, I | 1 |
| Suri, V | 1 |
| Dhawan, V | 1 |
| Ganguly, NK | 1 |
| Bo, S | 1 |
| Gentile, L | 1 |
| Repetti, E | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Redon, J | 1 |
| Donskov, AS | 1 |
| Golub', GV | 1 |
| Anikina, SA | 1 |
| Saltykova, NG | 1 |
| Sviderskaia, NS | 1 |
| Prilepo, NA | 1 |
| Feofanova, ID | 1 |
| Liese, AD | 1 |
| Hense, HW | 1 |
| Döring, A | 1 |
| Stieber, J | 1 |
| Keil, U | 1 |
| Torres, RJ | 1 |
| Sancho, T | 1 |
| Moreno, A | 1 |
| Cabrera, R | 1 |
| Aguirre, A | 1 |
| Puig, JG | 1 |
| Hayashi, M | 1 |
| Ueda, Y | 1 |
| Hoshimoto, K | 1 |
| Ota, Y | 1 |
| Fukasawa, I | 1 |
| Sumori, K | 1 |
| Kaneko, I | 1 |
| Abe, S | 1 |
| Uno, M | 1 |
| Ohkura, T | 1 |
| Inaba, N | 1 |
| Lauszus, FF | 1 |
| Rasmussen, OW | 1 |
| Lousen, T | 1 |
| Klebe, TM | 1 |
| Klebe, JG | 1 |
| Helkjaer, PE | 1 |
| Holm, J | 1 |
| Hemmingsen, L | 1 |
| Kaupke, CJ | 1 |
| Vaziri, ND | 1 |
| Powers, DR | 1 |
| Gonzales, E | 1 |
| Acién, P | 1 |
| Lloret, G | 1 |
| Lloret, M | 1 |
| Ford, HC | 1 |
| Lim, WC | 1 |
| Chisnall, WN | 1 |
| Pearce, JM | 1 |
| Feiks, A | 1 |
| Nowotny, C | 1 |
| Rudelstorfer, R | 1 |
| Gruber, W | 1 |
| Neunteufel, W | 1 |
| Krusell, LR | 2 |
| Steel, K | 1 |
| Williams, TF | 1 |
| Fairbank, M | 1 |
| Knox, K | 1 |
| Ryckewaert, A | 1 |
| Kuntz, D | 1 |
| Caraway, WT | 1 |
| Goldstein, JL | 1 |
| Fialkow, PJ | 1 |
| Malhotra, KK | 1 |
| Kathpalia, SC | 1 |
| Goulatia, RK | 1 |
| Chalmers, TM | 1 |
| Nikolov, GS | 1 |
| Schonheyder, F | 1 |
| Gregersen, G | 1 |
| Hansen, HE | 1 |
| Skov, PE | 1 |
| Talbott, JH | 1 |
| Dyszy-Laube, B | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria[NCT03118739] | Phase 2 | 60 participants (Actual) | Interventional | 2017-05-18 | Completed | ||
| Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes[NCT03887416] | Phase 4 | 225 participants (Anticipated) | Interventional | 2019-04-12 | Recruiting | ||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D[NCT02017171] | Phase 3 | 530 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic® Using Two Hour Neoral® Monitoring.[NCT02058875] | Phase 4 | 0 participants (Actual) | Interventional | 2014-02-28 | Withdrawn (stopped due to The study funder retracted their grant funding offer before contract signed.) | ||
| Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria[NCT01375322] | Phase 4 | 226 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03118739)
Timeframe: Baseline
| Intervention | mL/min/1.73m2 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 59.2 |
| Placebo | 68.1 |
"Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.~This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation." (NCT03118739)
Timeframe: Baseline
| Intervention | Units on a scale (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 60.4 |
| Placebo | 60.6 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (change in percentage in LV dimension) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -14.10 |
| Placebo | -15.37 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.6371 |
| Placebo | 0.7588 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.4833 |
| Placebo | 0.5258 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -2.3143 |
| Placebo | -2.7591 |
(NCT03118739)
Timeframe: Baseline
| Intervention | ms (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 81.13 |
| Placebo | 82.31 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (change in percentage in LV dimension) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -12.07 |
| Placebo | -12.21 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (percentage of LV volume) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 59.77 |
| Placebo | 60.19 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 161.47 |
| Placebo | 161.50 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 66.43 |
| Placebo | 64.63 |
(NCT03118739)
Timeframe: Baseline
| Intervention | g (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 110.27 |
| Placebo | 110.82 |
(NCT03118739)
Timeframe: Baseline
| Intervention | g/mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.696 |
| Placebo | 0.687 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 95.05 |
| Placebo | 96.86 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (change in percentage in LV dimension) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 43.47 |
| Placebo | 46.45 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -0.7673 |
| Placebo | -0.7797 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -0.6278 |
| Placebo | -0.6552 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 2.1059 |
| Placebo | 2.1220 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 1.40 |
| Placebo | 1.19 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/L (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 1.579 |
| Placebo | 1.313 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.410 |
| Placebo | 0.358 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 7.51 |
| Placebo | 7.02 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/g (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 459.05 |
| Placebo | 411.55 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | ms (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -1.46 |
| Placebo | -1.67 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | g (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 1.80 |
| Placebo | 2.63 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | g/mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.049 |
| Placebo | 0.053 |
LS Mean Percentage Change (95% CI) from Baseline in UACR (NCT03118739)
Timeframe: From Baseline to 12 Weeks of Treatment
| Intervention | Precent change (Least Squares Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -48.65 |
| Placebo | -15.31 |
LS Mean Percentage Change (95% CI) from Baseline in UACR (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | Precent change (Least Squares Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -38.40 |
| Placebo | 21.40 |
LS Mean Percentage Change (90% CI) from Baseline in UACR Compared to Placebo (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | Precent change (Least Squares Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -49.26 |
| Placebo | NA |
Change from Baseline in Diastolic and Systolic Blood Pressure (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | mm/Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Diastolic BP, mmHg Baseline | Diastolic BP, mmHg 12 weeks (Change from baseline) | Diastolic BP, mmHg 24 weeks (Change from baseline) | Systolic BP, mmHg Baseline | Systolic BP, mmHg 12 weeks (Change from baseline) | Systolic BP, mmHg 24 weeks (Change from baseline) | |
| Placebo | 77.8 | -0.2 | 1.7 | 138.5 | -3.2 | -0.6 |
| Verinurad 9 mg+Febuxostat 80 mg | 74.7 | 1.6 | 2.0 | 136.4 | -0.8 | 0.4 |
Changes in Clinical Chemistry Values (CFB = Change for Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | % hemoglobin bound to glucose (Mean) | ||
|---|---|---|---|
| Baseline Hemoglobin A1C/Hemoglobin, % | Hemoglobin A1C/Hemoglobin, % 12 weeks (CFB) | Hemoglobin A1C/Hemoglobin, % 24 weeks (CFB) | |
| Placebo | 8.28 | 0.13 | 0.22 |
| Verinurad 9 mg+Febuxostat 80 mg | 8.14 | 0.20 | -0.14 |
Changes in Clinical Chemistry Values (CFB = Change for Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | pmol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline Aldosterone, pmol/L | Aldosterone, pmol/L 12 weeks (CFB) | Aldosterone, pmol/L 24 weeks (CFB) | Baseline NT-proBNP, pmol/L | NT-proBNP, pmol/L 12 weeks (CFB) | NT-proBNP, pmol/L 24 weeks (CFB) | |
| Placebo | 95.11 | 14.72 | 38.14 | 15.866 | 1.556 | 15.866 |
| Verinurad 9 mg+Febuxostat 80 mg | 134.58 | 1.12 | 9.14 | 23.230 | 4.621 | 6.267 |
LS Mean Percentage Change (95% CI) from Baseline in eGFR (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | -4.40 | 0.55 |
| Verinurad 9 mg+Febuxostat 80 mg | 1.25 | -1.73 |
"LS Mean Change (95% CI) from Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.~This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation." (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Units on a scale (Least Squares Mean) | |
|---|---|---|
| 12 weeks Change from Baseline | 24 weeks Change from Baseline | |
| Placebo | -5.9 | -5.5 |
| Verinurad 9 mg+Febuxostat 80 mg | 0.8 | 0.5 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | s^-1 (Mean) | |||||
|---|---|---|---|---|---|---|
| Diastolic Circumferential Strain Rate (s^-1) (CFB) | Diastolic Longitudinal Strain Rate (s^-1) (CFB) | Diastolic Radial Strain Rate (s^-1) (CFB) | Systolic Circumferential Strain Rate (s^-1) (CFB) | Systolic Longitudinal Strain Rate (s^-1) (CFB) | Systolic Radial Strain Rate (s^-1) (CFB) | |
| Placebo | -0.0384 | -0.0300 | 0.0201 | -0.0743 | -0.0021 | 0.2516 |
| Verinurad 9 mg+Febuxostat 80 mg | -0.0496 | -0.0043 | 0.2348 | 0.0115 | 0.0285 | -0.1917 |
Change from baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | % (change in percentage from baseline) (Mean) | |||
|---|---|---|---|---|
| LV Ejection Fraction (%) (CFB) | Circumferential Strain (%) (CFB) | Longitudinal Strain (%) (CFB) | Radial Strain (%) (CFB) | |
| Placebo | 0.59 | -0.07 | 0.53 | 1.44 |
| Verinurad 9 mg+Febuxostat 80 mg | -2.08 | -0.25 | 0.29 | -2.29 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | mL (Mean) | ||
|---|---|---|---|
| LV End-diastolic Volume (mL) (CFB) | LV End-systolic Volume (mL) (CFB) | LV Stroke Volume (mL) (CFB) | |
| Placebo | -4.93 | -2.48 | -2.44 |
| Verinurad 9 mg+Febuxostat 80 mg | -5.39 | 1.33 | -6.73 |
LS Mean Percentage Change (95% CI) from Baseline in Serum Creatinine (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 3.44 | 0.02 |
| Verinurad 9 mg+Febuxostat 80 mg | -0.60 | 1.93 |
LS Mean Percentage Change (95% CI) from Baseline in Serum Cystatin C (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 0.114 | 3.951 |
| Verinurad 9 mg+Febuxostat 80 mg | 3.252 | 5.412 |
LS Mean Percentage Change (95% CI) from Baseline in Serum High Sensitivity C-reactive Protein (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 11.665 | 9.793 |
| Verinurad 9 mg+Febuxostat 80 mg | 35.863 | -8.002 |
LS Mean Percentage Change (95% CI) from Baseline in sUA (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 6.86 | 4.73 |
| Verinurad 9 mg+Febuxostat 80 mg | -56.81 | -61.93 |
Changes in Urinalysis (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | mg/dL (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Protein, mg/dL | Protein, mg/dL 12 weeks (CFB) | Protein, mg/dL 24 weeks (CFB) | Baseline Urine Albumin, mg/dL | Urine Albumin, mg/dL 12 weeks (CFB) | Urine Albumin, mg/dL 24 weeks (CFB) | Baseline Urine Creatinine, mg/dL | Urine Creatinine, mg/dL 12 weeks (CFB) | Urine Creatinine, mg/dL 24 weeks (CFB) | Baseline Urine Urate, mg/dL | Urine Urate, mg/dL 12 weeks (CFB) | Urine Urate, mg/dL 24 weeks (CFB) | |
| Placebo | 65.74 | -4.07 | 11.40 | 35.8905 | -0.3019 | 11.6049 | 86.25 | 12.95 | 8.53 | 23.960 | 3.560 | 2.294 |
| Verinurad 9 mg+Febuxostat 80 mg | 72.01 | -11.40 | -16.73 | 38.0907 | -9.4766 | -6.9482 | 96.52 | 5.06 | 7.58 | 28.354 | -13.394 | -10.732 |
Changes in Urinalysis (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | mg/g (Mean) | ||
|---|---|---|---|
| Baseline Protein/Creatinine, mg/g | Protein/Creatinine, mg/g 12 weeks (CFB) | Protein/Creatinine, mg/g 24 weeks (CFB) | |
| Placebo | 828.52 | -155.44 | 177.11 |
| Verinurad 9 mg+Febuxostat 80 mg | 945.56 | -185.33 | -98.60 |
Geometric mean of urinary albumin excretion rate (AER) during the last three months of the treatment period (Visits 15 and 16), adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group. (NCT02017171)
Timeframe: Last three months of treatment period (Weeks 142 and 156)
| Intervention | ug/min (Least Squares Mean) |
|---|---|
| Allopurinol | 47.9 |
| Placebo | 37.4 |
Geometric mean of two urinary albumin excretion (AER) measurements at the end of the 2-month wash-out period following the 3-year treatment period, adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group. (NCT02017171)
Timeframe: End of the 2-month wash-out period following the 3-year treatment period (week 164)
| Intervention | ug/min (Least Squares Mean) |
|---|---|
| Allopurinol | 42.9 |
| Placebo | 31.7 |
Glomerular filtration rate (GFR) at 4 months after randomization, estimated from serum creatinine and cystatin C and adjusted for the eGFR at baseline. (NCT02017171)
Timeframe: 4 months after randomization (week 16)
| Intervention | ml/min/1.73 m2 (Least Squares Mean) |
|---|---|
| Allopurinol | 70.3 |
| Placebo | 70.0 |
Glomerular filtration rate time trajectory from baseline to end of the 2-month wash-out period (week 164) estimated from quarterly serum creatinine measurements (eGFR). eGFR slopes were estimated by a linear mixed-effects model for longitudinal eGFR measures using a multiple imputation technique for missing values. Positive values denote increasing eGFR over time, negative values denote declining eGFR over time. (NCT02017171)
Timeframe: Weeks 0, 4, 16, 32, 48, 64, 80, 96, 112, 128, 156, and 164 (from baseline to the end of washout period)
| Intervention | ml/min/1.73 m2/year (Least Squares Mean) |
|---|---|
| Allopurinol | -2.4 |
| Placebo | -2.1 |
Risk of cardiovascular events defined as the composite of CVD death (ICD-10 code I10 to I74.9), myocardial infarction, stroke (ischemic or hemorrhagic), coronary artery bypass grafting, or percutaneous coronary intervention in the allopurinol arm as compared to placebo.Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression). (NCT02017171)
Timeframe: Up to the end of the 2-month wash-out period following the 3-year treatment period (week 0 to 164)
| Intervention | Participants (Count of Participants) |
|---|---|
| Allopurinol | 15 |
| Placebo | 9 |
Glomerular filtration rate (GFR) at the end of the 2-month wash-out period following the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline. (NCT02017171)
Timeframe: End of the 2-month wash-out period following the 3-year treatment period (week 164)
| Intervention | ml/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Allopurinol | 61.2 |
| Placebo | 61.2 |
Glomerular filtration rate (GFR) at the end of the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline. (NCT02017171)
Timeframe: End of the 3-yr treatment period (week 156)
| Intervention | ml/min/1.73 m2 (Least Squares Mean) |
|---|---|
| Allopurinol | 61.3 |
| Placebo | 61.0 |
Glomerular filtration rate time trajectory estimated from iohexol disappearance GFR (iGFR) measurements at weeks 0, 80, 156, and 164. iGFR slopes were estimated by a linear mixed-effects model for longitudinal iGFR measures using a multiple imputation technique for missing values. Positive values denote increasing GFR over time, negative values denote declining iGFR over time. (NCT02017171)
Timeframe: Weeks 0, 80, 156, and 164 (from baseline to the end of washout period)
| Intervention | ml/min/1.73 m2/year (Least Squares Mean) |
|---|---|
| Allopurinol | -3.0 |
| Placebo | -2.5 |
Risk of serum creatinine doubling or end stage renal disease (ESRD) in the allopurinol arm as compared to placebo. Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression). (NCT02017171)
Timeframe: Up to the end of the 2-month wash-out period following the 3-year treatment period (Week 0 to Week 164)
| Intervention | Participants (Count of Participants) |
|---|---|
| Allopurinol | 13 |
| Placebo | 11 |
10 reviews available for uric acid and Albuminuria
| Article | Year |
|---|---|
The Effect of Allopurinol on Renal Outcomes in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.
Topics: Albuminuria; Allopurinol; Diabetes Mellitus; Diabetic Nephropathies; Female; Humans; Kidney; Male; U | 2022 |
Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Humans; Hypertension; | 2019 |
[The First Step Aiming at the Prevention of Hypertension and Atherosclerosis. Identification of Individuals at High Risk of Hypertension].
Topics: Albuminuria; Ankle Brachial Index; Atherosclerosis; Biomarkers; Blood Pressure; Cardiovascular Disea | 2015 |
Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Topics: Albuminuria; Animals; Blood Pressure; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Gluc | 2017 |
Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy.
Topics: Albuminuria; Cystatins; Cytokines; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Kidne | 2008 |
Chronic kidney disease: a marker of cardiovascular disease.
Topics: Albuminuria; Anemia; Biomarkers; Blood Urea Nitrogen; Cardiovascular Diseases; Creatinine; Glomerula | 2009 |
Hypertensive renal vascular disease and cardiovascular endpoints.
Topics: Albuminuria; Biomarkers; C-Reactive Protein; Disease Progression; Erythropoietin; Glomerular Filtrat | 2006 |
[Hypertension, Type II diabetes mellitus and macroangiopathy: risk factors and their association].
Topics: Albuminuria; Alcohol Drinking; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Exercise; Female; H | 1994 |
[Polymetabolic syndrome].
Topics: Albuminuria; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin; | 1995 |
[Renal manifestations of hyperuricemia].
Topics: Acute Kidney Injury; Albuminuria; Cortisone; Gout; Hematuria; Humans; Kidney Calculi; Kidney Disease | 1972 |
26 trials available for uric acid and Albuminuria
| Article | Year |
|---|---|
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Topics: Aged; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2021 |
The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial.
Topics: Albuminuria; Allopurinol; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephro | 2018 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Topics: Aged; Albuminuria; Allopurinol; Arachidonic Acid; Blood Pressure; C-Reactive Protein; Cardiac Surgic | 2013 |
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Topics: Adiponectin; Aged; Albuminuria; Blood Pressure; Comorbidity; Creatinine; Double-Blind Method; Enzyme | 2014 |
Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatini | 2014 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Topics: Aged; Albuminuria; Allopurinol; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creati | 2015 |
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Albuminuria; beta 2-Microglobulin; Enzyme Inhibitors; Fatty Acid-Binding Pr | 2015 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pr | 2015 |
[Clinical implication of endothelial dysfunction in patients with essential arterial hypertension and urate dysbolism with renal damage].
Topics: Adult; Albuminuria; Carotid Intima-Media Thickness; Endothelin-1; Endothelium, Vascular; Female; Hum | 2011 |
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Hu | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiot | 2012 |
Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia.
Topics: Adult; Albuminuria; Carotid Artery Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventric | 2007 |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2007 |
Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Gl | 1994 |
Effects of losartan on renal function in patients with essential hypertension.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Com | 1996 |
Long-term therapy with an ACE inhibitor, temocapril, reduces microalbuminuria in essential hypertension.
Topics: Albuminuria; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cough; | 1998 |
Frequency and determinants of white coat hypertension in mild to moderate hypertension: a primary care-based study. Monitorización Ambulatoria de la Presión Arterial (MAPA)-Area 5 Working Group.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure Determination; Blood Pressure Monitoring, Am | 1999 |
Excretion of tamm-horsfall protein in patients with uric acid stones.
Topics: Albuminuria; Biomarkers; Citrates; Female; Humans; Hydrogen-Ion Concentration; Kidney Tubules, Dista | 1999 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia.
Topics: Adult; Albuminuria; beta 2-Microglobulin; Biopsy; Blood Urea Nitrogen; Capillaries; Creatinine; Endo | 2002 |
Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; beta 2-Microglobulin; Blood Pressure; Clinical Tria | 1986 |
Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls--a proximal tubular effect?
Topics: Adult; Albuminuria; beta 2-Microglobulin; Blood Pressure; Body Water; Humans; Hypertension; Kidney T | 1987 |
Clinical experience with Ibuprofen in the treatment of rheumatoid arthritis.
Topics: Albuminuria; Alkaline Phosphatase; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspa | 1969 |
164 other studies available for uric acid and Albuminuria
| Article | Year |
|---|---|
Endogenous fructose is correlated with urinary albumin creatinine ratios and uric acid in type 2 diabetes mellitus.
Topics: Albumins; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Fructose; Humans; Uric Acid | 2021 |
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Topics: Albuminuria; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Controlled Clinical Trials a | 2021 |
Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study.
Topics: Aged; Albuminuria; Animals; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2021 |
The association between glycaemic level and lipid profile with Albuminuria in Iraqi type 2 diabetes patients - A cross sectional study.
Topics: Adult; Aged; Albuminuria; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic N | 2021 |
Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease.
Topics: Albuminuria; Cohort Studies; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Insuf | 2022 |
Correlation of dehydroepiandrosterone with diabetic nephropathy and its clinical value in early detection.
Topics: Albumins; Albuminuria; Biomarkers; Cholesterol; Creatinine; Dehydroepiandrosterone; Diabetes Mellitu | 2022 |
Impaired kidney function biomarkers and risk of severe COVID-19: Analysis of population-based cohort data.
Topics: Adult; Albuminuria; Biomarkers; COVID-19; Cross-Sectional Studies; Cystatin C; Genetic Predispositio | 2022 |
Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations.
Topics: Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; East Asian | 2022 |
Nontraditional Risk Factors for Progression Through Chronic Kidney Disease Risk Categories: The Coronary Artery Risk Development in Young Adults Study.
Topics: Adult; Albuminuria; Biomarkers; Coronary Vessels; Disease Progression; Glomerular Filtration Rate; H | 2023 |
Editorial: from albuminuria to uric acid - emerging risk factors beyond lipids.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Humans; Lipids; Risk Factors; Uric Acid | 2023 |
Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study.
Topics: Albuminuria; Aldosterone; Blood Pressure; Case-Control Studies; Essential Hypertension; Humans; Hype | 2023 |
Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female | 2019 |
Changes in Water Soluble Uremic Toxins and Urinary Acute Kidney Injury Biomarkers After 10- and 100-km Runs.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Albuminuria; Arginine; Biomarkers; Creatinine; Fem | 2019 |
Microalbuminuria mediates the association between serum uric acid and elevation of blood pressure: a longitudinal analysis in the Gusu cohort.
Topics: Adult; Albuminuria; Asian People; Blood Glucose; Blood Pressure; Cohort Studies; Female; Humans; Hyp | 2020 |
Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Blood Transfusion; Child; Cohort Studies; Cross-Sectio | 2020 |
Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Cohort Studies; Creatinine; Female; France; Glomerular Fil | 2020 |
Uric Acid Is Not Associated With Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Correla | 2021 |
Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats.
Topics: Acute Kidney Injury; Albuminuria; Animals; Antineoplastic Agents; Caspase 3; Cisplatin; Creatinine; | 2021 |
Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in Ins
Topics: Albuminuria; Ameloblasts; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease | 2020 |
Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; F | 2020 |
Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?
Topics: Albuminuria; Diabetes Mellitus, Type 2; Febuxostat; Humans; Naphthalenes; Propionates; Pyridines; Re | 2021 |
Usefulness of Extra Virgin Olive Oil Minor Polar Compounds in the Management of Chronic Kidney Disease Patients.
Topics: Aged; Aged, 80 and over; Albuminuria; Aldehydes; Antioxidants; Azotemia; Biomarkers; Body Compositio | 2021 |
Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.
Topics: Adult; Aged; Albuminuria; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; M | 2022 |
Markers of Kidney Function and Longitudinal Cognitive Ability Among Older Community-Dwelling Adults: The Rancho Bernardo Study.
Topics: Aged; Albuminuria; Cognition; Female; Humans; Independent Living; Kidney Function Tests; Longitudina | 2021 |
Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Actins; Albuminuria; Animals; Blood Pressure; Cyclic N-Oxides; Deoxygua | 2017 |
Metabolic syndrome, serum uric acid and renal risk in patients with T2D.
Topics: Acute Kidney Injury; Aged; Albuminuria; Blood Pressure; Body Mass Index; Cholesterol, HDL; Databases | 2017 |
The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study.
Topics: Aged; Aged, 80 and over; Albuminuria; C-Reactive Protein; Cohort Studies; Cost Savings; Cost-Benefit | 2017 |
Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2.
Topics: Aged; Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle | 2018 |
The Association between Serum Uric Acid and Renal Damage: The Takahata Study - New Insights.
Topics: Albuminuria; beta 2-Microglobulin; Cardiovascular Diseases; Creatinine; Female; Glomerular Filtratio | 2018 |
Analysis on influencing factors of abnormal renal function in elderly patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Typ | 2020 |
Single-marker and multi-marker approaches to appraise the relationships between biomarkers and microalbuminuria in Chinese middle-aged and elderly from communities: a cross-sectional analysis.
Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; C-Reactive Protein; China; Cross-Sectional Studies | 2018 |
Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; China; Cross-Sectional Studies; Female; Hum | 2018 |
Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic N | 2019 |
A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study.
Topics: Adult; Aged; Albumins; Albuminuria; Creatinine; Cross-Sectional Studies; Diet; Edible Grain; Female; | 2019 |
Uromodulin in a Pathway Between Decreased Renal Urate Excretion and Albuminuria.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cross-Sectional Studies; Female; Genotype; Glomerular Filtrati | 2019 |
Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mel | 2019 |
Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes.
Topics: Aged; Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2019 |
Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular | 2019 |
Urine albumin and serum uric acid are important determinants of serum 25 hydroxyvitamin D level in pre-dialysis chronic kidney disease patients.
Topics: Adolescent; Adult; Albumins; Albuminuria; Cross-Sectional Studies; Female; Glomerular Filtration Rat | 2019 |
Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease.
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Cystatin C; Diabetes Mellitus; Female; Glomerular Filtrat | 2013 |
Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats.
Topics: Albuminuria; Animals; Blood Glucose; Case-Control Studies; Creatinine; Diabetes Mellitus, Experiment | 2013 |
Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in taiwan.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Female; Humans; Hyperuricemia; Incidence; Male; M | 2013 |
[Relationship between glomerular filtration rate, uric acid, and parathyroid hormone in children].
Topics: Adolescent; Albuminuria; Blood Pressure; Body Mass Index; Calcium; Child; Child, Preschool; Creatini | 2013 |
Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.
Topics: Adult; Albuminuria; Creatinine; Cystatin C; Diabetes Mellitus, Type 1; Disease Progression; Female; | 2014 |
Serum uric acid level is associated with the development of microalbuminuria in Korean men.
Topics: Adult; Age Factors; Albuminuria; Asian People; Cohort Studies; Creatinine; Diabetes Complications; D | 2014 |
Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients.
Topics: Albuminuria; C-Reactive Protein; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fem | 2013 |
Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population.
Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; Cross-Sectional Studies; Humans; Hypertension; Hyp | 2014 |
Serum uric acid concentration and asymptomatic hyperuricemia.
Topics: Albuminuria; Humans; Hypertension; Hyperuricemia; Male; Uric Acid; Vascular Stiffness | 2014 |
Reply to letter to the editor from Professor Viroj Wiwanitkit, Bankok, Thailand.
Topics: Albuminuria; Humans; Hypertension; Hyperuricemia; Male; Uric Acid; Vascular Stiffness | 2014 |
Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study.
Topics: Aged; Albuminuria; Biomarkers; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti | 2014 |
Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients.
Topics: Adult; Albuminuria; Aorta; Body Mass Index; Cross-Sectional Studies; Female; Humans; Hypertension; H | 2014 |
Low protein diet inhibits uric acid synthesis and attenuates renal damage in streptozotocin-induced diabetic rats.
Topics: Albuminuria; Animals; Cell Proliferation; Cell Size; Diabetes Mellitus, Experimental; Diabetic Nephr | 2014 |
The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort.
Topics: Absorption; Adult; Albuminuria; Cardiovascular Diseases; Chi-Square Distribution; Disease Progressio | 2014 |
Serum uric acid and target organ damage in essential hypertension.
Topics: Adult; Aged; Albuminuria; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Female; Humans; | 2014 |
Protective effect of bioflavonoid myricetin enhances carbohydrate metabolic enzymes and insulin signaling molecules in streptozotocin-cadmium induced diabetic nephrotoxic rats.
Topics: Albuminuria; Animals; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cadmium Chloride; Carbohydrate | 2014 |
Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2014 |
[Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder
Topics: Albuminuria; beta 2-Microglobulin; Biomarkers; Chemokine CCL2; Comorbidity; Endothelin-1; Endotheliu | 2014 |
Self-rated health and adverse events in CKD.
Topics: Acid-Base Equilibrium; Aged; Albuminuria; Area Under Curve; Biomarkers; C-Reactive Protein; Cause of | 2014 |
Nephron hypertrophy and glomerulosclerosis and their association with kidney function and risk factors among living kidney donors.
Topics: Adult; Age Factors; Albuminuria; Body Mass Index; Female; Glomerular Filtration Rate; Glomeruloscler | 2014 |
Serum uric acid concentration is associated with early changes of glomerular filtration rate in patients with diabetes type 1 without increased albumin excretion.
Topics: Adult; Albuminuria; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Early Diagnosis; | 2014 |
Persistence of cardiovascular risk factors in women with previous preeclampsia: a long-term follow-up study.
Topics: Adult; Albuminuria; Cardiovascular Diseases; Carotid Intima-Media Thickness; Case-Control Studies; F | 2015 |
A prospective controlled study of living kidney donors: three-year follow-up.
Topics: Albuminuria; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Case-Control Studies; Circadian Rhy | 2015 |
Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensinogen; Biomarkers; Blood Pressure; Circadian | 2015 |
Tenofovir monotherapy for hepatitis B after 1 year does not produce renal dysfunction, but is associated with hyperparathyroidism not related to vitamin D.
Topics: Adult; Albuminuria; Alkaline Phosphatase; Antiviral Agents; beta 2-Microglobulin; Creatinine; Cystat | 2016 |
Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Albuminuria; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2015 |
Uric acid is associated with microalbuminuria and decreased glomerular filtration rate in the general population during 7 and 13 years of follow-up: The Tromsø Study.
Topics: Aged; Albuminuria; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Ma | 2015 |
Subclinical target organ damage in normotensive and prehypertensive patients.
Topics: Albuminuria; Blood Pressure; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Natriuretic | 2017 |
Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)].
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; G | 2016 |
[Clinico-pathological characteristics and prognosis of IgA nephropathy patients with microalbuminuria and deposition of complement C3].
Topics: Albuminuria; Complement C3; Creatinine; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Kaplan-Me | 2016 |
[Clinical Significance of Urinary Microalbumin to Creatinine Ratio in Physical Examinations].
Topics: Albuminuria; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Mass Index; China; Cholesterol | 2016 |
Can Solid-Organ-Transplanted Patients Perform a Cycling Marathon? Trends in Kidney Function Parameters in Comparison With Healthy Subjects.
Topics: Adult; Albuminuria; Bicycling; Case-Control Studies; Creatinine; Exercise; Female; Glomerular Filtra | 2016 |
[Correlation between serum free fatty acid level and estimated glomerular filtration rate in type 2 diabetic patients].
Topics: Albuminuria; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glomerular Filt | 2016 |
Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community - The Hisayama Study.
Topics: Albuminuria; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Middle Aged; Renal Insuffici | 2016 |
Relationship between red cell distribution width and early renal injury in patients with gestational diabetes mellitus.
Topics: Acute Kidney Injury; Adult; Albuminuria; Blood Urea Nitrogen; China; Creatinine; Cross-Sectional Stu | 2016 |
Association of Serum Uric Acid Concentration with Diabetic Retinopathy and Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; Logi | 2016 |
The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome.
Topics: Adiposity; Adult; Albuminuria; Biomarkers; Blood Pressure; Chi-Square Distribution; Creatinine; Cros | 2016 |
The Association Between Adiponectin, Serum Uric Acid and Urinary Markers of Renal Damage in the General Population: Cross-Sectional Data from the Tromsø Study.
Topics: Adiponectin; Albuminuria; Biomarkers; Cross-Sectional Studies; Female; Humans; Kidney Diseases; Male | 2016 |
The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitu | 2017 |
Oxidative Stress Participates in the Associations Between Serum Uric Acid and Albuminuria in the Obesity.
Topics: Adiposity; Adult; Albuminuria; Blood Pressure; Humans; Metabolic Syndrome; Obesity; Oxidative Stress | 2017 |
Response to Letter to the Editor entitled Oxidative Stress Participates in the Associations Between Serum Uric Acid and Albuminuria in Obesity.
Topics: Adiposity; Adult; Albuminuria; Blood Pressure; Humans; Metabolic Syndrome; Obesity; Oxidative Stress | 2017 |
The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes.
Topics: Adult; Albuminuria; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetic Nephrop | 2017 |
Excretion rates of 1,5-anhydro-D-glucitol, uric acid and microalbuminuria as glycemic control indexes in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; | 2017 |
Association between serum uric acid, metabolic syndrome and microalbuminuria in previously untreated essential hypertensive patients.
Topics: Adult; Aged; Albuminuria; Cross-Sectional Studies; Female; Humans; Hypertension; Male; Metabolic Syn | 2009 |
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.
Topics: Adolescent; Adult; Albuminuria; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic | 2009 |
Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.
Topics: Albuminuria; Allopurinol; Animals; Blood Pressure; Blood Urea Nitrogen; Cell Line; Diabetes Mellitus | 2009 |
Levels of retinol-binding protein 4 and uric acid in patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Ty | 2009 |
Effect of short-term high-protein compared with normal-protein diets on renal hemodynamics and associated variables in healthy young men.
Topics: Adult; Albuminuria; Blood Pressure; Cross-Over Studies; Dietary Proteins; Glomerular Filtration Rate | 2009 |
Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study.
Topics: Adult; Albuminuria; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; F | 2010 |
The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Blood Pressure; | 2010 |
High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.
Topics: Adolescent; Adult; Albuminuria; Creatinine; Cystatin C; Diabetes Mellitus, Type 1; Disease Progressi | 2010 |
Very low-grade albuminuria reflects susceptibility to chronic kidney disease in combination with cardiovascular risk factors.
Topics: Adult; Albuminuria; Cardiovascular Diseases; Chronic Disease; Cohort Studies; Creatinine; Cross-Sect | 2010 |
Prevalence and risk factors for renal artery stenosis and chronic kidney disease in Japanese patients with peripheral arterial disease.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Angiography; Asian People; Cholesterol, LDL; Como | 2010 |
Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice.
Topics: Acetylglucosaminidase; Albuminuria; Animals; beta 2-Microglobulin; Blood Urea Nitrogen; Carrier Prot | 2011 |
Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus.
Topics: Albuminuria; Blood Glucose; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic | 2011 |
The anomalies associated with congenital solitary functioning kidney in children.
Topics: Abnormalities, Multiple; Adolescent; Albuminuria; Child; Child, Preschool; Female; Hospitals, Univer | 2011 |
[Endothelial function in patients with arterial hypertension and impaired uric acid metabolism].
Topics: Adult; Albuminuria; Antihypertensive Agents; Endothelin-1; Endothelium, Vascular; Female; Humans; Hy | 2010 |
Factors associated with diabetic nephropathy in subjects with proliferative retinopathy.
Topics: Aged; Albuminuria; Blood Pressure; Blood Sedimentation; C-Reactive Protein; Circadian Rhythm; Diabet | 2012 |
Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients.
Topics: Adult; Aged; Albuminuria; C-Reactive Protein; Coronary Artery Disease; Creatinine; Cross-Sectional S | 2011 |
Risk profile in chronic kidney disease stage 3: older versus younger patients.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Atherosclerosis; Cardiovascular Diseases; Diabeti | 2011 |
Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study.
Topics: Adult; Aged; Albuminuria; Causality; Cross-Sectional Studies; Female; Genotype; Glomerular Filtratio | 2011 |
[The relationship between urinary albumin excretion and serum uric acid in general population].
Topics: Adult; Aged; Albuminuria; Creatinine; Female; Humans; Kidney Diseases; Lipids; Logistic Models; Male | 2011 |
Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus.
Topics: Albuminuria; Atherosclerosis; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 2012 |
Hyperuricemia and microalbuminuria are separately and independently associated with prehypertension among Chinese Han women.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Asian People; Biomarkers; Blood Pressure; Chi-Squ | 2012 |
High-normal serum uric acid is associated with albuminuria and impaired glomerular filtration rate in Chinese type 2 diabetic patients.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Mal | 2011 |
Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension.
Topics: Adult; Albuminuria; Biomarkers; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension; Lon | 2012 |
[Diagnostic value of radom spot albuminuria to creatinine ratio in women with preeclampsia].
Topics: Adult; Albumins; Albuminuria; Biomarkers; Creatinine; Female; Humans; Pre-Eclampsia; Predictive Valu | 2012 |
Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease.
Topics: Albuminuria; Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blood Urea Nitrogen; | 2012 |
The association between serum uric acid and renal damage in a community-based population: the Takahata study.
Topics: Adult; Aged; Albuminuria; beta 2-Microglobulin; Creatinine; Cross-Sectional Studies; Female; Humans; | 2013 |
The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study.
Topics: Aged; Albuminuria; C-Reactive Protein; Creatinine; Elective Surgical Procedures; Female; Gout; Human | 2013 |
Tubular injury: the first symptom of hypertensive kidney involvement?
Topics: Acetylglucosaminidase; Adolescent; Adult; Albuminuria; Biomarkers; Female; Fructose; Glucose Toleran | 2003 |
Severe pre-eclampsia and maternal thyroid function.
Topics: Adult; Albuminuria; Blood Pressure; Case-Control Studies; Female; Gestational Age; Humans; Pre-Eclam | 2003 |
[A PARTICULAR TYPE OF FUNCTIONAL RENAL INSUFFICIENCY: HYPOXIC GLOMERULO-NEPHROPATHY].
Topics: Albuminuria; Anuria; Blood Chemical Analysis; Bronchitis; Glomerulonephritis; Hemoglobins; Hypoxia; | 1964 |
[Microalbuminuria and atherosclerosis risk factors in potentially healthy men--preliminary data].
Topics: Adult; Albuminuria; Apolipoproteins A; Apolipoproteins B; Arteriosclerosis; Biomarkers; Blood Glucos | 2004 |
The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage.
Topics: Albuminuria; Biomarkers; Blood Pressure; Body Mass Index; Echocardiography; Female; Follow-Up Studie | 2005 |
[Relation between diabetes compensation, albuminuria and biochemical parameters and the results of stress myocardial SPECT in asymptomatic type 2 diabetics].
Topics: Albuminuria; C-Reactive Protein; Coronary Circulation; Coronary Disease; Diabetes Mellitus, Type 2; | 2004 |
Serum uric acid and target organ damage in primary hypertension.
Topics: Adult; Albuminuria; Biomarkers; Carotid Artery Diseases; Female; Humans; Hypertension; Hypertrophy, | 2005 |
Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients.
Topics: Albuminuria; Analysis of Variance; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Carotid | 2005 |
Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan.
Topics: Aged; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Lo | 2005 |
Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy.
Topics: Aged; Albuminuria; Bilirubin; Biomarkers; Blood Glucose; C-Reactive Protein; Chromatography, High Pr | 2006 |
Serum uric acid is associated with microalbuminuria in prehypertension.
Topics: Albuminuria; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Logistic Models; Male; Mid | 2006 |
Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors.
Topics: Adolescent; Albuminuria; Blood Glucose; Cardiovascular Diseases; Child; Female; Glucose Tolerance Te | 2006 |
Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension.
Topics: Albuminuria; Arteries; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Cardiovascular Dis | 2007 |
Sympathoadrenergic and metabolic factors are involved in ambulatory blood pressure rise in childhood obesity.
Topics: Adolescent; Albuminuria; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Ma | 2008 |
Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Atherosclerosis; Biomarkers; Body Mass Index; Carotid A | 2009 |
The relationship between obesity and transforming growth factor beta on renal damage in essential hypertension.
Topics: Adult; Albuminuria; Blood Glucose; Body Mass Index; Case-Control Studies; Creatinine; Female; Humans | 2007 |
High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.
Topics: Adult; Age Factors; Albuminuria; Antihypertensive Agents; Blood Pressure; Cross-Sectional Studies; C | 2008 |
Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemo | 2008 |
Relationship between serum uric acid levels and urinary albumin excretion in patients with heart failure.
Topics: Aged; Albuminuria; Biomarkers; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration | 2008 |
[Cardiological risk factors in Swiss men].
Topics: Adult; Albuminuria; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Coronary Disease; Glyco | 1967 |
The influence of intravenous furosemide on the renal excretion pattern of protein and protein degradation products.
Topics: Aged; Aging; Albuminuria; beta 2-Microglobulin; Creatine; Furosemide; Humans; Hydrogen-Ion Concentra | 1984 |
Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta-adrenoceptor-blocking drugs.
Topics: Adult; Albuminuria; beta 2-Microglobulin; Blood Pressure; Female; Heart Rate; Humans; Hypertension; | 1982 |
Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Diabeti | 1996 |
[Microalbuminuria as one of the early diagnostic signs of kidney involvement in patients with a purine metabolic disorder].
Topics: Adult; Albuminuria; Female; Gout; Hematuria; Humans; Kidney Diseases; Male; Purines; Recurrence; Tim | 1996 |
N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment.
Topics: Acetylglucosaminidase; Adult; Aged; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Antirheuma | 1997 |
Kidney function in phasic insulin dependent diabetes mellitus in Jamaica.
Topics: Albuminuria; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 1997 |
Microalbuminuria and renal haemodynamics in essential hypertension.
Topics: Adult; Aged; Albuminuria; Female; Hemodynamics; Humans; Hypertension; Kidney; Kidney Function Tests; | 1997 |
Reversed circadian blood pressure rhythm preserves fetal growth in preeclamptic pregnancy.
Topics: Adolescent; Adult; Alanine Transaminase; Albuminuria; Aspartate Aminotransferases; Blood Pressure; B | 1997 |
Which urinary proteins are decreased after angiotensin converting--enzyme inhibition?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Body Weight; C | 1998 |
[Clinical and diagnostic significance of microalbuminuria and activity of tubular enzyme N-acetyl-beta-D-glucosaminidase (NAG) determination in patients with hyperuricosuria].
Topics: Acetylglucosaminidase; Adolescent; Adult; Albuminuria; Female; Humans; Immunochemistry; Kidney Disea | 1998 |
Urinary N-acetyl-beta-glucosaminidase in the prediction of preeclampsia.
Topics: Acetylglucosaminidase; Adult; Albuminuria; Clinical Enzyme Tests; Creatinine; Female; Humans; Hypert | 1998 |
Diabetes mellitus after liver transplantation: a possible relation with the nutritional status.
Topics: Albuminuria; Bilirubin; Blood Glucose; Blood Proteins; C-Peptide; Cyclosporine; Diabetes Mellitus, T | 1998 |
Microalbuminuria and hypertension in nondiabetic Japanese men.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus; Glucose Tole | 1999 |
Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Blood Proteins; Chi-Square | 1999 |
Do regular high protein diets have potential health risks on kidney function in athletes?
Topics: Adult; Albuminuria; Blood Glucose; Calcium; Case-Control Studies; Creatinine; Diet Records; Dietary | 2000 |
Estimation of cord blood erythropoietin in pre-eclampsia and eclampsia.
Topics: Adult; Albuminuria; Apgar Score; Biomarkers; Birth Weight; Blood Pressure; Case-Control Studies; Ecl | 2000 |
Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cohort Studies; Diabetes M | 2000 |
[Relationship between mass of the left ventricular myocardium and uric acid metabolic imbalance in patients with arterial hypertension].
Topics: Adult; Albuminuria; Body Mass Index; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Ki | 2001 |
Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95.
Topics: Adult; Age Factors; Aged; Albuminuria; Body Constitution; Cholesterol; Cholesterol, HDL; Diabetes Co | 2001 |
Serum uric acid levels and microalbuminuria in mild hypertensive patients.
Topics: Albuminuria; Female; Humans; Hypertension; Male; Middle Aged; Uric Acid | 2000 |
Ambulatory blood pressure as predictor of preeclampsia in diabetic pregnancies with respect to urinary albumin excretion rate and glycemic regulation.
Topics: Adolescent; Adult; Albuminuria; Birth Weight; Blood Glucose; Blood Pressure; Blood Pressure Monitori | 2001 |
Intra-individual changes in concentrations of urinary albumin, serum albumin, creatinine, and uric acid during normal pregnancy.
Topics: Albuminuria; Creatinine; Female; Humans; Pregnancy; Reference Values; Serum Albumin; Uric Acid | 1992 |
Erythropoietin in preeclampsia.
Topics: Adult; Albuminuria; Blood Cell Count; Blood Pressure; Creatine; Erythropoietin; Female; Humans; Pre- | 1991 |
Perinatal morbidity and mortality in pregnancy hypertensive disorders: prognostic value of the clinical and laboratory findings.
Topics: Adult; Albuminuria; Estriol; Female; Fetal Growth Retardation; Gestational Age; Hematocrit; Humans; | 1990 |
Renal function and electrolyte levels in hyperthyroidism: urinary protein excretion and the plasma concentrations of urea, creatinine, uric acid, hydrogen ion and electrolytes.
Topics: Acetylglucosaminidase; Adult; Aged; Albuminuria; Chlorides; Creatinine; Female; Humans; Hydrogen-Ion | 1989 |
[Assessment of edema in pregnancy].
Topics: Adult; Albuminuria; Birth Weight; Blood Urea Nitrogen; Creatinine; Female; Gestational Age; Humans; | 1989 |
Laboratory screening in the evaluation and placement of geriatric patients.
Topics: Aged; Albuminuria; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Cell Count; Blood Chemic | 1974 |
The scientific development of clinical chemistry to 1948.
Topics: Albuminuria; Animals; Biochemistry; Blood; Blood Glucose; Chemistry, Clinical; Colorimetry; Edema; E | 1973 |
The Alström syndrome. Report of three cases with further delineation of the clinical, pathophysiological, and genetic aspects of the disorder.
Topics: Adolescent; Adult; Albuminuria; Blood Cell Count; Blood Urea Nitrogen; Child; Complement System Prot | 1973 |
Urolithiasis and nephropathy in gout.
Topics: Adult; Aged; Albuminuria; Female; Gout; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Ur | 1973 |
[Podagric arthropathy].
Topics: Adolescent; Adult; Albuminuria; Algeria; Cardiovascular Diseases; Child; Child, Preschool; Cholester | 1971 |
Renal clearances of different amino acids in Wilson's disease before and after treatment with penicillamine.
Topics: Adolescent; Albuminuria; Amino Acids; Aminohippuric Acids; Copper; Female; Glomerular Filtration Rat | 1971 |
Diagnosis of gout.
Topics: Albuminuria; Arthritis; Arthritis, Rheumatoid; Colchicine; Colic; Diagnosis, Differential; Gout; Hum | 1970 |
[Kidney function tests in acute leukemias in children].
Topics: Albuminuria; Child; Hematuria; Humans; Kidney Function Tests; Leukemia; Uric Acid | 1966 |
Studies of renal function in acute leukemia in children.
Topics: Albuminuria; Child; Glomerular Filtration Rate; Hematuria; Hemorrhagic Disorders; Humans; Kidney Fun | 1966 |